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ABSTRACT 
Genetic polymorph isms in the folate metabolizing pathway and breast cancer 
survival 
Nandita Das 
April 26, 2012 
Genes in folate metabolizing pathway are responsible for modulating key 
enzymes in folate metabolisms necessary for DNA synthesis and repair and 
influence DNA methylation. Irregularity in DNA methylation may modify tumor 
phenotype response to chemotherapy and abnormal DNA synthesis, and repair 
may lead to carcinogenesis. This dissertation project tested the hypothesis that 
the key genes in the folate metabolizing pathway, namely 
Methylenetetrahydrofolate reductase (MTHFR) , betaine-homocysteine-
methyltransferase (BHMT) , 5-methyltetrahydrofolate-homocysteine (MTR), 5-
methyltetrahydrofolate-homocysteine methyltransferase reductase (MTRR) , and 
serine hydroxymethyltransferase (SHMT1) and folate receptor 1 (FOLR1) 
influences all- cause and breast cancer-specific mortality and the association 
between the genes in the folate metabolizing pathway and breast cancer-specific 
survival is modified by chemotherapy and estrogen receptor (ER) status. Gene-
gene interactions among the genes in the folate metabolizing pathway were also 
tested in this study. Data for this study were obtained from the New Mexico site 
of the Health, Eating, Activity, and Lifestyle (HEAL) Study for 446 incident 
vii 
primary breast cancer cases (stage 0 - lilA). Over 11.46 years of follow-up, there 
were 67 deaths; 22 due to breast cancer. In the Cox proportional hazards 
analysis, women who carried at least one variant allele for MTRR G66A 
polymorphism had statistically significant inverse associations with all- cause 
(Hazard Ratio [HR]: 0.51; 95% confidence interval [CI]: 0.3-0.8; p-value <0.01) 
and breast cancer-specific mortality (HR: 0.40; 95% CI: 0.2-0.9; p-value <0.01). 
There were no statistically significant interactions with chemotherapy or ER 
status. Synergistic multiplicative interaction was observed between BHMT 
A742G and FOLR1 G606A polymorph isms in predicting breast cancer-specific 
mortality (p for interaction: 0.03). In this sample, there was antagonistic 
multiplicative interaction between MTRR G66A and MTHFR C677T 
polymorphisms in predicting breast cancer-specific mortality (p for interaction: 
0.08). These results should be further explored in larger cohorts and in clinical 
populations. 
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According to the American Cancer Society's 2012 report1, breast cancer is 
the second leading cause of cancer death among women in the US, with over 
forty thousand expected deaths in 2012 alone 1. Studies show that folate 
deficiency may be associated with breast cancer risk and may also influence 
breast cancer-specific survivaI2-4 . Folate plays an important role in DNA 
methylation2 . It helps in the synthesis of purines, thymidylate, glycine, and 
methionine thus serving an important role in nucleotide synthesis2. Its deficiency 
could, therefore, lead to abnormal DNA methylation. Abnormal DNA synthesis, 
and repair may lead to carcinogenesis and irregularity in DNA methylation may 
modify response to chemotherapl6. Genes in folate- or one-carbon 
metabolizing pathway are responsible for modulating key enzymes in folate 
metabolisms necessary for DNA synthesis and repair and influence DNA 
methylation2 7 8. Methylenetetrahydrofolate reductase (MTHFR) , betaine-
homocysteine-methyltransferase (BHM7), 5-methyltetrahydrofolate-
homocysteine (MTR), 5-methyltetrahydrofolate-homocysteine methyltransferase 
reductase (MTRR), and serine hydroxymethyltransferase (SHMT1) are some of 
the key genes in the folate metabolizing pathway responsible for the enzymes in 
folate metabolism. MTHFR, MTR, MTRR, BHMT and SHMT1 act as catalysts in 
1 
the conversion of 5, 1 O-methylTHF to 5-methyleneTHF, a donor for the 
remethylation of homocysteine to methionine, the precursor for S-
adenosylmethionine (SAM) 9. Folate receptor 1 (FOLR1), which lies outside the 
one-carbon metabolizing pathway, modulates cellular folate availability, which 
may indirectly influence intracellular metabolism and subsequently DNA 
methylation, and synthesis. Also taken together these genes regulate folate 
availability and metabolism. Polymorphic variations in these genes, in the 
presence of folate deficiency, could lead to abnormal DNA methylation, and 
synthesis 10. 
Several studies have investigated the association of MTHFR 
polymorph isms, dietary folate, and breast cancer risk11 -17 . Three studies have so 
far investigated the association between MTHFR polymorph isms and breast 
cancer survival12 18 19 of which only one study, the Long Island Breast Cancer 
Studi 9 has investigated the associations of the other genes in the folate 
metabolizing pathway with breast cancer survival. The Long Island Breast 
Cancer Studi 9 with an average follow-up of 5.6 years and a sample size of 
1,508 women diagnosed with both in situ and invasive breast tumors, reported an 
association between the MTHFR (C677T) polymorphism and breast cancer 
mortality. In their sample, estrogen receptor (ER) status significantly modified 
the effect of the association between C677T breast cancer-specific survival. The 
Shanghai Breast Cancer Studlo did not detect any significant association 
between MTHFR polymorph isms and five year survival. C677T genotype non-
significantly increased breast cancer-specific mortality among women diagnosed 
2 
with late stage (stage III-IV) tumor. Martin et al18 observed similar inverse 
association between C677T and breast cancer-specific mortality. They also 
investigated the effects of ER status and race on the association between 
MTHFR polymorph isms and breast cancer-specific mortality. In their sample, 
women with ER negative tumors had worse survival for both C677T and A 1298C 
and race (Caucasian vs. African American) modified the effect of MTHFR 
polymorph isms on breast cancer-specific mortality. 
Study Objectives 
The overall objective of this dissertation is to investigate the association 
between genetic variants in the folate metabolizing pathway and the genes 
responsible for maintaining blood folate level and breast cancer-specific survival 
and to examine the effects of chemotherapy use, ER status, and folate intake on 
these associations. Additionally, gene-gene interaction was evaluated. 
The specific aims of this dissertation include: 
1. To investigate the associations between genetic variants in the folate 
metabolizing pathway (BHMT, SHMT1, MTR and MTRR) and the gene 
responsible for maintaining blood folate level (FOLR1) in relation to 
breast cancer-specific survival, adjusted for age at diagnosis, 
ethnicity, stage, chemotherapy, ER-status, folate and B-complex 
vitamin, alcohol and energy intake. 
Genes in folate metabolizing pathway are responsible for modulating key 
enzymes in folate metabolisms necessary for DNA synthesis and repair. Several 
studies have investigated the association of MTHFR polymorph isms and breast 
3 
cancer risk 11-17particularly with respect to the modifying effect of MTHFR 
polymorph isms on the association between folate intake and breast cancer risk. 
Associations between genes in the folate metabolizing pathway and risk of 
colorectal cancer and adenomas have also been investigated21 22. Studies have 
also investigated the association between MTHFR polymorph isms and breast 
cancer survival12 18 19but only one cohort study, the Long Island Breast Cancer 
Study 19 has so far investigated the association between other genes in the 
folate metabolizing pathway and breast cancer mortality. 
2. To investigate if breast cancer survival associated with each of these 
genes differs when other genes in the same pathway are present 
(gene- gene interaction). 
Since the enzymes in a pathway may interact with each other, it is important to 
investigate the interactions among genes in the folate metabolizing pathway on 
breast cancer-specific survival. Studies have not yet investigated the effect of 
gene-gene interactions on folate metabolizing pathway in predicting breast 
cancer survival. Hence this dissertation project, sought to test if the presence of 
variants of one gene influences the associations of variants in other genes in the 
folate metabolizing pathway with breast cancer survival. 
3. To investigate if breast cancer survival associated with each of these 
genes differs with use of (a) chemotherapy, and (b) ER status. 
In breast cancer cell lines 2324, mice models 24 and breast cancer patients 2025-27, 
MTHFR polymorphisms are reported to alter the chemo-sensitivity of commonly 
used chemotherapeutic agents in breast cancer treatment but few studies have 
4 
investigated the effects of chemotherapy on the associations of genes in the 
folate metabolizing pathway with breast cancer-specific survival. ER status is a 
widely used prognostic marker and indicator of breast cancer treatmene8 . Since 
the Martin et al18 and Xu et al19 have investigated the effects of ER status on the 
association of genes in the folate metabolizing and breast cancer survival, the 
current study is an attempt to replicate and extend their findings. 
In short, this dissertation will help to enrich the current literature on the 
folate metabolizing pathway and breast cancer survival. Since ER status is a 
widely accepted prognostic marker in suggesting breast cancer treatment, its 
effects on the genes in the pathway in predicting breast cancer survival rates 
may help clinicians in future to decide the types of treatment suggested to 
women with a certain genetic make-up. The findings of current study may also 
help to clarify research to chemotherapy. Future studies should include cohorts 





Among the U,S, women breast cancer is the second leading cause of 
cancer death, following lung cancer1, Not including skin cancer, it is also the 
most commonly diagnosed form of cancer among women, According to the 
estimates of the American Cancer Society, the life time risk for being diagnosed 
with breast cancer in the United States is approximately 1 in 8 and the probability 
of dying from it is about 1 in 3529 , During 2012 alone, an estimated 226,870 new 
cases of invasive and 63,300 new cases of in situ breast cancer will be 
diagnosed in the US1, In the past few decades the rates of survival following 
breast cancer diagnosis has significantly increased mostly due to improvement 
treatment and early detection29 , 
PRIMARY INDEPENDENT VARIABLES 
1. Folate metabolizing Pathway 
Folate deficiency may be associated with breast cancer risk and breast 
cancer-specific survival2-4 , Folate helps in the synthesis of purines, thymidylate, 
glycine, and methionine thus serving an important role in nucleotide synthesis 
and intracellular methylation4 , Its deficiency could, therefore, lead to abnormal 
DNA methylation, Genes in the folate metabolizing pathway like MTHFR (C677T; 
6 
rs1801133 and A 1298C; rs1801131), BHMT (A742G; rs3733890), MTR (A2756; 
rs1805087), MTRR (G66A; rs1801394), SHMT1 (G1420A;rs1979277) and 
FOLR1 (G606A; rs3796517) encode for key enzymes in folate metabolism, which 
is essential in the process of DNA methylation, synthesis and repair 278. DNA 
methylation involves addition of the methyl group to the 5th position of the 
cytosine pyrimidine ring which helps regulates cell development and 
differentiation. Methylation occurs in CpG (cytosine-phosphate-guanine) islands 
rich in C and G, upstream of the promoter region and is facilitated by a group of 
enzymes called the DNA methyletransferases. Figure 1 provides a diagrammatic 
representation of the pathway. To investigate the influence of these genes, one 
of their single nucleotide polymorph isms (SNP) which has been shown in the 
literature to be associated with other cancers in humans was selected. Table1 
lists the genes in the folate metabolizing pathway along which are of interest in 
this dissertation project, their location, function, sequence showing nucleotide 
change, allele frequency estimates and the populations from which the frequency 
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, " one carbon unIts fOf meth!orune. ccrcc 
ase 1} thymidylate, and purines AA -35 
rs1979277 (C1420T) synlhesis::~ ·. 
Binds with f olre aod and its 
FOLR1 derivativE'S and lransport 5- 11 Q13.3-Q14.1 AAATIAAGTGGATGGAA. EU 31-50 
(folate receptor 1) melhylTHF into celis::, (71903173- GAGAAACTA[AfG]ACATA AS 15-22 
r53796517 (G606A) 71907366 bp) GCACTITTg~CCATTTAT SSA 30·50 
AA ~22 
~EU (EtIrop~an); AS (Asian); SSA (sub Saharan Afncan); AA (AfncanAmerican;' " Location type: MIssense 
Following is a brief overview of the genes in the folate metabolizing pathway that 
are investigated in this dissertation : 
MTHFR (C677T and A1298C): 
MTHFR is an enzyme that is coded by the gene with the same name and 
symbol located at chromosome 1, p36.22 between 11 ,785 ,525 and 11 ,788,057 
bp 30 . It is a key enzyme in folate metabol ism, which is essential in the process of 
DNA methylation , synthesis and repair2 7 8. Figure 2 below provides a 
diagrammatic representation of chromosome 1 showing the location of MTHFR 
gene. 
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Figure 2: Diagrammatic representation of chromosome 1 showing MTHFR 
Studies on genetic polymorph isms of MTHFR have identified two common single 
nucleotide polymorph isms (SNP) : C677T (rs1801133) and A1298C (rs1801131) 
with population minor allele frequencies of 32% and 23% respectivell1. 
Results from the Long Island Breast Cancer Study suggested significant 
reduction in breast cancer-specific mortality rates among C677T allele carriers 
compared to non-carriers (HR= 0.58; 95% CI : 0.38 - 0.89) 19. They also reported 
that estrogen receptor-progesterone receptor (ER/PR) status modified the effect 
of C677T polymorphism breast cancer mortal ity (p = 0.05) . No significant 
association was observed between A 1298C genotype and breast cancer 
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mortality. The Shanghai BC StudlO did not detect any significant association 
between MTHFR polymorph isms and five year survival. C677T genotype 
significantly increased the likelihood (HR= 2.97, 95% CI: 1.10, 7.98) of long term 
mortality among patients diagnosed with late stage (stage III-IV) disease .. 
Martin et al18 observed similar inverse association between C677T and breast 
cancer-specific mortality. They also investigated the effects of ER status and 
race on the association between MTHFR polymorph isms and breast cancer-
specific mortality. In their sample, women with ER negative tumors had worse 
survival (C677T: HR: 0.36; 95% CI: 0.12-1.35; A1298C: HR: 2.70; 95% CI: 1.17-
6.23) and there was significant interaction between race (Caucasian vs African 
American) and breast cancer mortality (C677T, p for interaction: 0.03; A1298C, p 
for interaction: 0.09). These studies, however, did not investigate potential effect 
modification of the association between MTHFR polymorph isms and breast 
cancer mortality by the use of chemotherapy. During the preliminary phases of 
this study, associations between MTHFR polymorph isms and breast cancer 
mortality, particularly with respect to the modifying effect of chemotherapy on 
these associations were investigated using data from all three sites of the Health, 
Eating, Activity and Lifestyle (HEAL) Study (Refer to chapter IV for details related 
to findings of the preliminary study; unpublished results). 
MTR (A2756G): 
MTR encodes for the enzyme 5-methyltetrahydrofolate-homocysteine 
methyltransferase, which is a Vitamin B12 dependent enzyme32 (figure 1). It is 
also known as methionine synthase. It catalyzes the methylation of 
12 
homocysteine to methionine and simultaneous ly converting 5-methylTHF to THF 
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Figure 3: Diagrammatic representation of chromosome 1 showing MTR 
A2756G (rs 1805087) is a common variant of the gene which substitutes the 
amino acid aspartic acid to glycine at codon 9193435 . Although studies have 
reported the effects of MTR A2756G on plasma homocysteine in humans, they 
are inconsistent about the levels of homocysteine across genotypes of A275634-
36 . Evidence of the association between folate and B complex vitamins and 
homocysteine levels is limited37 . The current literature is also inconsistent about 
the effects of MTR A2756G on breast 3538-41 and colon cancer2242 risk , 
particularly with relation to established risk factors like menopausal status, 
alcohol intake, and folate intake. There is insufficient research to date on the 
association of MTR and breast cancer mortality. 
MTRR (G66A): 
MTRR gene encodes for the enzyme methionine synthase reductase 
which acts as catalyst in the final step of the conversion of homocysteine to 
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Figure 4: Diagrammatic representation of chromosome 5 showing MTRR 
G66A (rs1801394) is a common variant of the gene which substitutes isoleucine 
with meth ionine at codon 2243 and as the name suggests (reductase) , activates 
methionine synthase, also known as MTR by acting as a carbon donor for 
homocysteine remethylation . Like the MTR polymorphism, studies have 
consistently observed an association between homocysteine levels and MTRR 
G66A but while some studies report elevated levels of homocysteine among 
carriers of AA genotype44 45 others report decrease in homocysteine levels 46 . 
Studies also did not find significant associations between folate , B-complex 
vitamins , and alcohol intake and MTRR G66A genotypes. In order to better 
understand the impact of the variant of MTRR G66A in predicting breast cancer 
survival , research on this polymorphism is due. 
BHMT (A742G): 
BHMT encodes for the protein betaine-homocysteine methyltransferase 
and is located in chromosome 5 (5q13.1-q15) (Figure 5) . Unlike MTR, MTRR, 
and MTHFR, BHMT is not involved in the folate-dependent re-methylation 
process. Instead BHMT utilizes betaine, a metabolite of chol ine, as its carbon 
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Figure 5: Diagrammatic representation of chromosome 5 showing BHMT 
Studies have observed significant correlation between plasma homocysteine and 
plasma betaine levels and have suggested that plasma betaine is capable of 
lowering plasma homocysteine levels47 . So BHMT plays an important role in the 
re-methylation of homocysteine in the folate metabolizing pathway when the 
pathway is compromised due to mutations in the MTRR or MTR polymorph isms 
or deficiencies in vital nutrients4748 . As for MTHFR polymorphisms, studies have 
investigated the association of BHMT A742G with risk for 
hyperhomocysteinemia49 , vascular diseases49 50 and congenital diseases like 
neural tube defect51 , and Downs Syndrome52 . Studies have yet to investigate the 
association between BHMT A742G and breast cancer survival. 
SHMT1 (C1420T/G1420A): 
SHMT1, sometimes called cytosolic serine hydroxymethyltransferase 
(cSHMT1), encodes for the protein of the same name and is one of the less 
frequently studied genes in the folate metabolizing pathway. It is located in 
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Figure 6: Diagrammatic representation of chromosome 17 showing SHMT1 
It has a functional Leu> Phe polymorphism (C1420T/G1420A; rs1979277) . It is 
vitamin-B6 dependent enzyme that facilitates SAM synthesis and catalyzes the 
conversion from 5-methylTH F to 5-1 O-methylene TH F. It has been suggested 
that carriers of the minor alleles of the SHMT1 G1420A polymorphism may 
decrease production of the 5-1 O-methylTHF for pyrimidine synthesis. This may 
reduce levels of DNA methylation through negative feedback which may in turn 
result in decreased 5-methylTHF production and accumulation of THF, leading to 
carcinogenesis53 . It has been studied in re lation to risk for acute lymphocytic 
leukemia54, malignant lymphoma55, and colorectal cancer5356. The current 
research is an attempt to contribute to the literature on the SHMT1 polymorphism 
and breast cancer mortality. 
FOLR1 (A606G): 
As mentioned already, although outside of the folate metabolizing 
pathway, the folate receptor a enzyme encoded by the FOLR1 gene is located in 
chromosome 11 (11q13 .3-q14.1) (Figure 6) plays an important role in the uptake 
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Figure 7: Diagrammatic representation of chromosome 11 showing FOLR1 
While dietary folate is known to exist in apolyglutamated state, folic acid from 
fortified foods and supplements is in monoglutamated state and is taken up by 
the cell differently. Folic acid does not require hydrolysis before absorption . 
Once folate is inside the intestinal cells , regardless of poly or mono-glutamated 
states, various coenzymes convert it to 5-methyl THF prior to release into the 
bloodstream. Folate receptor a binds with fol ic acid and its derivatives and helps 
transport 5-methylTHF for SAM synthesis . Depending on the type of tissue, 5-
methyl THF is also taken up by tissues via folate receptor a from the 
bloodstream57 . Like SHMT1, FOLR1 G606A (rs3796517) is also one of the less 
frequently studied polymorphism associated with folate metabolism . Effects of 
FOLR1 polymorphisms have been investigated along with genes in the folate 
metabolizing pathway with respect to renal cel158 and prostate59 cancer risk. But 
stud ies have not yet investigated its association with breast cancer survival , so in 
this dissertation the effects of the variant of the FOLR1 G606A are explored . 
2. Chemotherapy: 
Biochemical studies have shown that besides being an anti-metabolite 
of folate , two metabolites of fluoropyrim idine (5-FU) a commonly used 
chemotherapeutic agent in breast cancer treatment, 5-fluoro-2' -deoxyuridine-5 '-
triphosphate and 5' -flurouridine-5 ' -triphosphate, can interfere with the level of 
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DNA stability and RNA functioning. Further, 5-fluoro-2'-deoxyuridine-5'-
monophosphate (5FdUMP), an active metabolite of 5-FU, forms a complex with 
TS and 5,1 O-methyleneTHF, which inhibits the function of TS which in turn 
depletes intracellular thymidylate resulting in suppression of DNA synthesis 60. 
Again, 5'-formyITHF, the precursor of 5, 10-methyleneTHF potentiates the 
cytotoxic effects of 5-FU by stabilizing the inhibition of 5, 1 O-methyleneTHF-TS-
5FdUMP complex. Studies have shown that MTHFR polymorphisms that 
increase the concentration of 5, 1 O-methyleneTHF may result in elevation of the 
cytotoxic levels of 5FU60 . Conversely, MTHFR polymorph isms that increase of 
accumulation of 5,10 -metheleneTHF may alter the cytotoxic effects of 
Methotrexate (MTX), another common chemotherapeutic agent61 . MTX inhibits 
dihydrofolate reductase, decreases intracellular 5,10 - methyleneTHF levels for 
the synthesis of thymidylate and inhibits the synthesis of purine. Accumulation of 
dihydrofolate can inhibit the activities of TS and other enzyme61 . These 
chemotherapeutic agents affect DNA synthesis and down-regulate cell 
replication. Experimental studies on breast cancer cell lines 2324, mice models 24 
and breast cancer patients 2025-27 have shown that MTHFR polymorphisms 
influence the concentration and cellular pathway of folate metabolism altering 
their chemosensitivity. 
Some of the common chemotherapy medicines used currently for breast 
cancer treatment are abraxane, adriamycim, carboplatin, cytoxan, daunorubicin, 
doxil, ellence, fluorouracil also called 5-fluorouracil or 5-FU, gemzar, halaven, 
ixempra, methotrexate, mitomycin, navelbine, taxol, taxotere, thiotepa, 
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vincristine, and xeloda62 63. These chemotherapy medicines are, however, 
commonly used in combinations. The type of chemotherapy regimen 
recommended to a patient is dependent upon the patient's general health, 
menopausal status and clinical characteristics like the stage at diagnosis, 
hormone receptor status, HER2 status, and lymph node status. Some of the 
current standard chemotherapy regimens62 63 used for breast cancer treatment 
include: 
.:. Adriamycin and Taxotere (AT) 
.:. Adriamcycin and Cytoxan with or without Taxol or Taxotere (AC± T) 
.:. Cytoxan, Methotrexate, and Fluorouracil (CMF) 
.:. Cytoxan, Ellence, and Fluorouracil (CEF) 
.:. Fluorouracil, Adriamycin, and Cytoxan (FAC) 
.:. Cytoxan, Adriamycin, and Fluorouracil (CAF) 
.:. Taxotere, Adriamycin, and Cytoxan (TAC) 
.:. Gemzar, Ellemce, and Taxol (GET) 
Studies have not yet investigated the effect of various commonly used 
chemotherapy medicines on the association of BHMT, MTR, MTRR, SHMT, and 
FOLR1 and breast cancer survival. In this study, therefore, it was investigated if 
chemotherapy modified the associations of these genes with breast cancer 
survival. 
ER status: 
ER is a group of receptors that are activated by estrogen hormone 64. 
The main function of ER is to serve as a DNA binding transcription factor that 
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regulates gene expression 65. There were two reasons for investigating the 
effects of ER status on the association between genes in the folate metabolizing 
pathway and breast cancer survival. First, DNA methylation has been suggested 
in the literature to be associated with silencing of ER expression66-69 . The 
enzymes in the folate metabolizing pathway may influence ER status. Secondly, 
it is often hypothesized that tumorigenesis is triggered by binding of estrogen to 
the ER which stimulates proliferation of mammary cells decreasing the rate of 
cell division, DNA replication and mutation7o . Either way, normal cell cycle and 
DNA repair mechanisms are disrupted resulting in inhibition of apoptosis and 
tumor formation. ER-status is, therefore, a widely used prognostic marker and 
indicator of breast cancer treatment28. ER expression is an important marker for 
deciding whether or not a patient receives endocrine therapy (for example 
tamoxifen) as part of breast cancer treatment regimen. 
In the Long Island Breast cancer studi 9 a significant elevation of mortality 
rates was observed due primarily to breast cancer among C677T (MTHFR) allele 
carriers compared to non-carriers. Additionally, ER/PR status modified the 
association of C677T polymorphism with all-cause mortality after breast cancer 
treatment. Martin et al18 also observed the effects of ER status on the 
association between both the MTHFR polymorph isms and breast cancer-specific 
mortality. In their sample, women with ER negative tumors had worse survival. 
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COVARIATES OF INTEREST 
1. Folate intake: 
Folate is essential for DNA methylation and nucleotide synthesis. Folate 
deficiency could, therefore, lead to abnormal DNA methylation 10. Epidemiological 
studies have shown that deficiency in folate could lead to breast 11-17, colorectal 
71-73, and endometrial 74 cancer and the effect of the deficiency is modified by 
MTHFR polymorph isms 11-1571-74. Recent studies on colorectal cancer have also 
shown that while folate in general is anti-neoplastic before the establishment of 
tumor foci, after the tumor is established it accelerates tumor proliferation75 76. 
While high consumption of folate reduces risk for colorectal cancer by 30-40% 
compared to lowest consumption of folate, timing of intake is crucial because the 
literature suggests that progression of premalignant to cancerous lesions is 
accelerated with high folate intake77 78. Since folate provides one carbon unit in 
the thymidylate synthase mediated conversion of dUMP to dTMP, its depletion 
could result in the accumulation of intracellular uracil resulting in the mis-
incorporation of uracil into DNA and increase in DNA damage79 80. 
2. Stage at diagnosis: 
Stage at diagnosis is another widely used prognostic marker that is an 
indicators for breast cancer treatment type 81 and for survival. Shrubsole et al 12 
in their study on MTHFR polymorph isms observed a non-significant elevation of 
risk (HR= 1.8; 95% CI: 0.79-4.14) for mortality due to breast cancer among IT 
genotype compared to carriers of CC genotype who were diagnosed at a later 
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stage (stage III-IV) and the risk was almost three fold higher (HR= 2.97; 95% CI: 
1.10-7.98) among those that survived longer than two years following initial 
diagnosis. Results from both the Long Island Breast Cancer Studl6 and the 
Shanghai Breast Cancer Study 20, indicated that C677T genotype significantly 
elevated the risk for breast cancer-specific mortality among patients diagnosed 
with late stage (stage III-IV) disease. The study by Martin and colleagues did not 
stratify on disease stage 18. 
3. Treatments type: 
Besides chemotherapy, tamoxifen therapy was a covariate of interest in 
this study. It is estimated that approximately 70% of breast cancer cases are ER 
positive7o and ER status is a clinical deciding factor for prescription of tamoxifen 
and aromatase inhibitors82 . ER bound to estradiol and tamoxifen induces 
different conformations in the receptor accounting for variation in functional 
activity. The drug tamoxifen, thus acts as an antagonist in breast cells and hence 
ideal for breast cancer treatment 70. As mentioned already, DNA methylation may 
influence the expression of ER66-69 . 
4. Demographic factors: 
Demographic factors like age, race/ethnicity, body mass index (BMI), 
reproductive factors like age at menarche, age at menopause, parity, etc., often 
used as surrogates for exposures to endogenous hormones, and exogenous 
hormones like DC and HRT use have been widely recognized as factors that 
influence survival following diagnosis and treatment of breast cancer 83-85. 
Although effect modification of the association between breast cancer risk and 
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MTHFR by menopausal status has been investigated, the findings of the existing 
literature have been non-significant and inconsistent 11 86. Studies have not yet 
investigated the influenced of menopausal status on breast cancer survival 
among women carrying various other polymorph isms in folate metabolizing 
pathway and genes responsible for folate intake. These covariates are, therefore, 
potential confounders in the investigation of the association between genes in the 
folate metabolizing pathway and breast cancer-specific survival. 
5. Other nutritional and life style factors: 
Biochemical studies have shown that B-complex vitamins are involved in 
the pathogenesis of breast cancer in several pathways. Deficiencies in vitamin B6 
(pyridoxine), B12 (cyanocobalamin), niacin causes DNA breakage and oxidative 
leision 87-89. Both vitamin B6 and B12 are directly involved in the folate 
metabolizing pathway (Figure 1). For instance, SHMT1 enzyme is dependent on 
vitamin B6 for purine synthesis necessary for conversion of homocysteine to 
methionene and also catalyzes the conversion from 5-methytetrahydrofolate to 5-
10-methyltetrahydrofolate. Vitamin B12 is directly involved in the methylation 
process via SAM synthesis. 
Studies have also shown the interaction of alcohol consumption and 
survival following diagnosis of breast cancer90-92 . Although the risk for early 
mortality due to breast cancer among women with 40 g/day alcohol consumption 
is elevated (HR= 2.00; 95% CI: 1.14-3.49) with low folate intake (200lJd/day), 
high levels (400IJd/day) of folate intake seems to have a protective effect against 
mortality (HR= 0.77; 95% CI: 0.33-1.80) due to breast cancer 90. 
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Dietary and lifestyle factors along with prognostic factors serve as 
potential confounders of the association between folate intake and survival 
following breast cancer diagnosis and treatment. Polymorph isms in the folate 
metabolizing pathway alter the concentration and cellular pathway of folate 
metabolism disrupting the sensitivity of chemotherapeutic drugs used in breast 
cancer treatment. 
6. Comorbidities: 
Studies have investigated the associations of the genes in folate 
metabolizing pathway on the etiology of colon cance~1 227693. It was therefore, 
intriguing to explore the percentage of the deaths due to cancer other than breast 
cancer in the HEAL sample can be attributable to colon cancer and if they serve 
as confounds. It was therefore, important to consider deaths due to other cancers 
that might confound the association between the genes in the folate metabolizing 
pathway and breast cancer survival. 
Studies have also shown that higher concentrations of homocysteine, an 
amino acid involved in SAM synthesis (see figure 1), elevate the risk of 
cardiovascular disease (CVD)9495. In presence of vitamin 8 12, MTR, BHMT, 
MTRR, and MTHFR catalyzes the conversion of homocysteine to methionine by 
remethylation. Under normal physiological conditions homocysteine is excreted 
by the kidney in moderate amounts96 but polymorph isms of genes involved in 
homocysteine metabolisms could increase the plasma concentration of 
homocysteine 9798 , which is thought to damage the vascular epithelium and 
thereby increase the risk for CVD991oo. Studies have also shown that vitamin 8 12 
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and folate are protective against CVD development101 . In the literature it is 
suggested that patients with vascular diseases and atherosclerosis have lower 
levels of folate and vitamin B12 concentrations 102 and vitamin B12 deficiency may 
elevate the homocysteine concentration and contribute plaque formation in the 
carotid arteri 03 . In other words, vitamin B12 deficiency is an important risk factor 
for both hyperhomocysteinemia and CVD 95. 
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CHAPTER III 
METHODS AND STATISTICAL PLAN 
INTRODUCTION 
This chapter presents the methods used for this dissertation. The chapter 
begins with a brief overview of the study population and the samples used in the 
study. It is followed by a list of study hypotheses, a description of the Cox 
Proportional Hazard method, primary dependent and independent variables and 
censorings used in the survival analysis. The section is followed by a list of the 
operational hypotheses and a description of the main effects and the interactions 
investigated in this dissertation project. There is a section on power analysis 
section and concludes with brief description of the genotyping process. 
STUDY POPULATION 
The Health, Eating, Activity, and Lifestyle (HEAL) Study is a population 
based, multicenter, multiethnic prospective cohort study in which 1,183 women 
with incident primary BC were enrolled to investigate the associations of weight, 
physical activity, diet, sex hormones, mammographic density, and other 
established risk factors with BC survival and quality of life. Women were recruited 
through three Surveillance, Epidemiology, and End Results (SEER) registries: at 
the Fred Hutchinson Cancer Research Center in Seattle, WA, the University of 
New Mexico and the University of Southern California. Details of the study aims 
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design, and recruitment procedures have been published previously 104-106. 
Briefly, in the New Mexico site a total of 615 women, age 18 years or older, 
diagnosed with in situ to stage lilA BC between July 1996 and March 1999 and 
living in Bernalillo, Sante Fe, Sandoval, Valencia, or Taos Counties were 
recruited. In the Seattle site, 202 women, between the age of 40 and 64 years, 
diagnosed with in situ to stage IliA BC between September 1997 and September 
1998 and living in King, Pierce, or Snohomish Counties were recruited. In Los 
Angeles (LA) site, 366 African American women with stage 0 to IliA primary BC 
who either participated in the LA portion of the Women's Contraceptive and 
Reproductive Experiences Study, which is a case-control study of invasive BC, or 
in a parallel case control study of in situ BC. Other eligibility criteria for the LA 
site included were born in the US, capable of speaking English, between the 
ages of 35 to 64 years and diagnosed with BC between May 1995 and May 
1998. Participants completed an in-person interview at baseline which was 
within their first year following diagnosis (an average of 7.5 months after 
diagnosis) and at 24 months after the baseline visit which was within their third 
year of diagnosis (an average of 31 months after diagnosis). During both time 
points biological specimens were collected. Data were collected again at 5 and 
10 years. Person years of follow-up are calculated from the date of diagnosis to 
12/31/2007 as the end point. For investigation of the SNPs associated with 
MTHFR gene samples from all three sites were used. A diagrammatic 
representation of the cohort is presented in Chapter 4. 
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To investigate the association of the SNPs corresponding to BHMT, MTR, 
MTRR, SHMT1, and FOLR1 genes and breast cancer mortality only the samples 
from New Mexico site was available. Of the 615 women enrolled at New Mexico, 
DNA was collected for 406 women at baseline and 409 at 24 months follow-up. 
Because DNA was collected twice, some women who did not provide samples at 
baseline provided them at follow-up. Thus, the total number of women with DNA 
available for this study was 462. Three hundred and sixty- eight had provided 
DNA during baseline as well as at 24 months follow-up interview, 36 at baseline 
only and 58 at follow-up only. During the preparation phase, all 416 samples 
were inventoried and sample selection was based on availability with first 
preference given to baseline DNA and, if a sample did not have enough DNA 
from baseline, the sample from the 24 months follow-up was used. For 12 
samples, there were insufficient amounts of DNA from both baseline and 24 
months follow-up to perform genotyping and one sample was compromised for 
an unknown reason and could not be genotyped for all five SNPs. A total of 446 
biological samples were used for the current investigation of which 137 (31 %) 
were collected during baseline and 309 (69%) were from 24 months follow-up 
interview. Figure 8 provides a diagrammatic representation of the cohort. 
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Enrollment at baseline: 615 
, , 




Archived DNA available: 
Baseline and follow up: 368 Insufficient DNA available: 12 
Baseline only: 36 ""'" Unable to genotype: 4 , 




DNA (baseline): 137 
DNA (24 months follow-up): 309 
Total DNA used: 446 
, 
" Mortality (11.46 years follow-up): 
All causes: 67 
Breast cancer-specific: 22 
Figure 8 Cohort definition for the New Mexico site of the Health, Eating, 
Activity, and Lifestyle (HEAL) Study and the number of events during 11.46 
years of follow-up 
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HYPOTHESIS 
Below are the study hypotheses: 
1. Main effect: 
Genes in one carbon metabolizing pathway (MTHFR, BHMT, SHMT1, 
MTR, MTRR, and FOLR1) are responsible for modulating key enzymes in 
folate metabolisms. Several case control studies 11-17 have investigated the 
association of MTHFR polymorph isms and breast cancer risk and breast 
cancer survival12 18 19but only one cohort study has so far investigated the 
association of the other genes in the folate metabolizing pathway and 
breast cancer survival. In this study, therefore, we test the following 
hypothesis: 
Women who carry at least one minor allele (dominant model) of the 
candidatel TAG SNP polymorph isms experience an increase in 
mortality; specifically breast cancer mortality within the first 11.46 
years of follow-up compared to women who carry two major alleles 
adjusting for relevant covariates. 
For example, carriers of the variant allele of C677T, a polymorphism of 
MTHFR gene, are reported reduced of breast cancer specific mortality 
rates 19. 
2. Gene-Gene interaction: 
Previous studies have not investigated the association of genes within the 
folate metabolizing pathway and breast cancer-specific survival. In this 
study, therefore, we test the following hypothesis: 
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Presence of other genes in the same pathway increases the all-cause, 
and breast cancer mortality rates among women who carried at least 
one minor allele of the candidate/TAG (BHMT, SHMT1, MTR, MTRR, 
and FOLR1) polymorph isms. 
3. Gene-Environment interaction: 
a) The current literature suggests possible biological associations between 
chemotherapy and breast cancer survival 6061, Genes in the folate 
metabolizing pathway may alter the levels of 5-10 methyleneTHF which 
may increase the levels of THF leading to increase in the cytotoxic levels 
of folate depleting chemotherapeutic agents, 5FU and MTX6061 , In this 
study, therefore, the following hypothesis was tested: 
Women who received chemotherapy and carried at least one minor 
allele (dominant model) of the candidate/TAG (BHMT, SHMT1, MTR, 
MTRR, and FOLR1) polymorph isms have increased rates of all-
cause, and breast cancer mortality compared to women who did not 
receive chemotherapy and carried two major alleles. 
b) The assessment of ER status influences the type of treatment a women 
receives which may influence her survival28 82 107, DNA methylation has 
been suggested to be associated with silencing of ER expression66-69 , 
Results from the Long Island Breast Cancer Study 19 suggested a 
significant interaction between MTHFR (C677T) and ER status for breast 
cancer survival. In this study, therefore, we test the following hypothesis: 
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Women diagnosed with ER negative tumors and carrying at least one 
minor allele (dominant model) of the candidate/TAG (BHMT, SHMT1, 
MTR, MTRR, and FOLR1) polymorph isms have increased rates of all-
cause, and breast cancer mortality compared to women with ER 
positive tumor who carried two major alleles. 
STATISTICAL PLAN 
To test the study hypotheses, Cox proportional-hazards (PH) analysis 
(SAS 9.2, PROC PH REG) was used to estimate all cause and breast cancer-
specific mortality for main effect and interaction with chemotherapy and ER 
status. 
The formula for the Cox PH model: 
p 
r{3ixi 
h(t,X) = ho (t) e i=1 
Here ho (t) is the baseline hazard at time t = 0 and X = (X11 X2, .. . Xp) are 
predictor variables that are independent of time. Here ho (t) is unspecified. Since 
the hazard function involves t and an exponential expression involving the X 
without t, it makes fitting the model non-negative. It is, therefore, robust non-
parametric, non-linear and non-negative model108. Parameters of the Cox model 
were obtained by maximing the likelihood function which is the joint probability of 
obtaining the data that is observed on the study subjects as a function of the 
unknown parameter's (f3) of the model under consideration 108. 
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Variables: 
Multivariate Cox proportional-hazards models were created for each of the 
six SNPs and potentially important nutritional, behavioral and/or demographic 
covariates to investigate gene-environment interaction. Following are the primary 
dependent and independent variables. 
Primary dependent variables or outcomes of interest: 
1. Overall survival/all-cause mortality 
2. Breast cancer-specific mortality 
Primary independent variables: 
1. Genotypes of interest: Genes (MTHFR (polymorph isms: C677T and 
A1298C), BHMT, MTR, MTRR, SHMT1, FOLR1 and RFC1) are 
coded as homozygous dominant (AA) = 0, heterozygous (AB) = 1 
and homozygous recessive (BB) = 2. 
2. Chemotherapy use: Although various chemotherapeutic agents 
were received either alone or in various combinations owing to 
sample size considerations (see chapter 4), chemotherapy was 
coded as a binary variable where no chemotherapy= 0 and 
chemotherapy= 1. 
3. Estrogen receptor status: Estrogen receptor (ER) status of the 
tumor was re-coded into ER-positive= 0 and ER- negative = 1. 
Covariates: 
Covariates of interest were adjusted for all models based on biological 
plausibility, and frequency distribution. Relevant covariates were subjected to 
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correlation and leverage analysis prior to being incorporated into the models. 
Covariates of interest based include: 
Potential confounders were adjusted in all models based on biological 
plausibility and frequency distribution. Relevant covariates were subjected to 
correlation and leverage analysis prior to being incorporated into the models. 
Covariates of interest included: 
1. Age at diagnosis (continuous): Based on the eligibility criteria, all 
subjects in the study were between ages 29 to 87 years at the time 
of breast cancer diagnosis. 
2. Ethnicity: Ethnicity was coded as Non-Hispanic White = 0 
(reference), and Hispanic= 1. 
3. Body Mass Index: The continuous variable BMI was created based 
on body weight and height. For the purpose of analysis it was re-
coded into four categories based on WHO recommendations: BMI 
<18.5 (underweight), BMI between 18.5 and 24.9 (normal), BMI 
between 25.0 and 29.9 (overweight) and BMI >= 30.0 (obese). The 
variable underweight was considered as the reference category. 
4. Menopausal status: Menopausal status was coded as a binary 
variable with pre-menopausal= 0 and post-menopausal= 1. 
5. Stage at diagnosis: Based on eligibility criteria only cases with in 
situ to stage lilA of breast cancer were included in the study. The 
stage of disease at diagnosis, was based on SEER defined, 
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Summary Stage 1977, composed of three sub-groups: in situ, 
localized, and regional. 
6. Treatment: Treatment was categorized as: no surgery= 0, surgery 
only= 1, surgery and radiation= 2, surgery and chemotherapy = 3 
and'surgery, radiation and chemotherapy= 4. 
7. Tamoxifen use: Tamoxifen use was coded as a binary variable; 
previous or present treated was coded as 1 and no treatment as O. 
8. Radiation therapy: Radiation therapy was coded as a binary 
variable; previous radiation was coded as 1 and no treatment as O. 
9. Oral contraceptive (OC) use: OC use was coded as a binary 
variable. If a subject reported receiving OC she was coded as 1 
else O. 
10. Hormonal therapy (HRT): HRT was coded as a binary variable. If a 
subject reported receiving HRT she was coded as 1 else O. 
11. Age at menarche: Age at menarche was used as a continuous 
variable. 
12. Age at menopause: Age at menopause was used as a continuous 
variable. 
13. Parity: Parity was coded as 0 for nulliparous subjects, and 1 for 
subjects with one or more live births. 
14. Family history of breast cancer: Family history of breast cancer was 
coded such that if a subject reported that she has no family history 
of breast cancer diagnosis she was coded as 0, she was coded as 
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1 if any 1 st degree relative(s) were diagnosed with breast cancer 
and 2 if any 2nd degree relative(s) and no 1st degree relative were 
diagnosed with breast cancer. 
15. Smoking status: Smoking is also coded as a binary variable. If a 
subject reported smoking the past or during the time of the 
interview (ever/current smoker) she was coded as 1. If she reported 
never smoking in her life she is coded as O. 
16. Alcohol intake: Like total folate intake variable, amounts of alcohol 
intake reported during 24 months interview was considered in the 
analysis. It was reported in mg/day of intake. Total alcohol intake 
was considered as continuous variable. For the purpose of analysis 
it was also re-coded in tertiles. All outliers were excluded from the 
analysis. 
17. Folate intake: Since Los Angeles site did not collect food intake 
data at baseline, data collected during 24 months interview was 
used in the analysis for investigating the two MTHFR 
polymorphisms. Given that there was strong correlation between 
baseline and 24-months total folate intake for the New Mexico and 
Seattle data justified the used of the 24 months food frequency 
data. But for investigating the other five genes, where only New 
Mexico samples were used baseline food frequency data were 
used. It was reported in IJg/day of intake. Total folate intake was 
considered as a continuous variable. For the purpose of analysis it 
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was also re-coded into tertiles where the lowest tertile was 
considered the reference category. All outliers (> 2000 IJg/day) 
were excluded from the analysis. 
18. B complex vitamin intake (B1, B2, B3, B6 and Bd: Like folate, the 
data for the rest of the B-complex vitamins, namely: niacin (B1), 
riboflabin (B2), thiamin (B3), vitamin-B6, and vitamin-B12 , were also 
used from the 24 months interview. It was reported in IJg /day of 
intake. All vitamin B variables were considered as continuous 
variables. For the purpose of analysis it was also recoded into 
tertiles. 
19. Total energy intake: Information on total energy intake was also 
used from 24 months interview data. It was reported in Kcal/day. It 
was used as a continuous variable. It was also recoded into teritles 
for the purpose of analysis. All outliers (> 13000 IJg/day) were 
excluded from the analysis. 
Censoring: 
A censored observation is said to occur when there is incomplete information for 
survival time. Following are the reasons for censoring to occur in the study. 
Primary outcomes: 
For all-cause mortality: 
1. End of follow-up: the subject does not experience death due to any 
cause before the study ends 
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2. Lost to follow-up: the subject withdraws from the study because of 
reasons not related to the study outcome (person moving to 
another location and not leaving any forwarding address, busy, not-
interested in participating in the study, etc.) 
For breast cancer specific mortality: 
1. End of follow-up: the subject does not experience death due to 
breast cancer before the study ends 
2. Lost to follow-up: the subject withdraws from the study because of 
reasons not related to the study (person moving to another location 
and not leaving any forwarding address, busy, not-interested in 
participating in the study, etc.) 
Although four different kinds of censoring are possible: right truncation, left 
truncation, right censoring and left censoring, this study focuses only on right 
censoring because the central idea behind survival analysis is to follow subjects 
over time and observe at which point in time the event of interest occurs, which in 
this study is all-cause death or breast cancer death. Thus, when an observation 
is right censored it means that the information is incomplete because an event 
was not experienced during the study time period or the individual was lost to 
follow-up or withdrew from the study108 
OPERATIONAL HYPOTHESIS 
Main effect: 
Equation for the multivariable model: 
h(t,X) = ho (t) exp [J31 X1 + J32X2 + J33X3+ .... J3pXp] 
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Where X1 is the gene under investigation (Example: MTHFR (C677T); 0= CC 
(wild type) and 1 = CTITT(variant)) and X2 through Xp are covariates of interest 
that are adjusted for in the model. The coefficients f31 ttirough f3p describes the 
main effects of the primary independent variables and covariates of interest. 
Interaction: 
Multivariable interaction model: 
h(t,X) = ho (t) exp U31X1 + f32X2 + 133 (X1* X2) + f34X4 
.. .. f3pXp] 
Where X1 is the gene under investigation (Example: MTHFR (C677T); 0= CC 
(wild type) and 1 = CT / TT (variant)) and X2 is a primary independent variable 
(Example: chemotherapy, 0 = no and 1 = yes). X4 through Xp are covariates of 
interest that are adjusted for in the model. The coefficients f31 and f32 describes 
the main effects of the gene and the primary independent variables respectively, 
f33 describes the increase or decrease in hazard ratio due to interactions between 
the gene and the primary independent variable. 
Multivariate interaction model testing dose or types of a treatment: 
h(t,X) = ho (t) exp [bX + C1Z1 + .... Ck-1Zk-1+ d1(X * Z1) + .... + dk-
1(X * Zk-1)] 
Where X1 is the gene under investigation (Example: MTHFR(C677T); 0= CC 
(wild type) and 1 = CT / TT (variant)), Z1 ... .lk-1 are types or levels of the primary 
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independent variable (Example: types of chemotherapy). The coefficients band 
C1 .. , Ck-1 describe the main effects of the gene and types or levels of the primary 
independent variable respectively, and d1 ... dk_1 describe increase or decrease in 
hazard ratio due to the interactions of the gene and types or levels of the primary 
independent variable. 
Gene-gene interaction was investigated based on allele and haplotype 
frequencies (PROC ALLELE and PROC HAPLOTYPE) of the genotype 
subgroups. Haplotype analysis was focused only on the two polymorphs of 
MTHFR gene. Covariates of interest were adjusted for all models based on 
biological plausibility, and frequency distribution. Relevant covariates were 
subjected to correlation and leverage analysis prior to being incorporated into the 
models. 
POWER CALCULATIONS 
The estimated minor allele frequencies of one carbon metabolizing genes 
in the general population are reported in table 3. The selection of the SNPs in 
each of the five genes is based on the following criteria: 
• Estimated allele frequency of the SNP is greater than 10 % and less than 
40 % 
• The studies that helped estimate the allele frequencies had a sample size 
greater than 1000 
• Allele frequencies used for power calculation (reported in table 3) were 




If f is the genotype frequency of interest and g=1-f, and 0 is the number of 
deaths after 10 years of follow-up (in this study), power to detect a hazard ratio 
IJ. if we use a one-sided test is calculated using the following equations. Here it is 
assumed that there are no ties in survival times and the power of the log-rank 
test depends on the sample size which in turn depends the number of deaths 109. 
Let Z1-a be the percentile corresponding to 0% probabilities, P [ Z > Z1-a ] = a and 
P [ Z < Z1-a ] = 1- a, where a= 1-0 or 1-[3, then from Hsieh et al we have, 
2 (Zl-a+ Zl-p) 
D = f 9 [10 g.1] 2 ---------------------------------- (1) 
=> D X [g X [logi1]2 = (Zl-a + Zl_p)2 
=> v7J X .JIg X logi1= Zl-a + Zl-P 
=> Zl-P = -VDlg X logi1- Zl-a ------------------------------------------(2) 
For a two-sided test, where 0 = 5% and 1- [3= 80%, Z1-a = 1.96 then 
P [ Z < Z1-a] = P [ Z < 1.96] = 0.975 
and 
P [ Z > Z1-a] = P [ Z > 1.96] = 0.025 
For a one sided test, Z1-a = 1.64 then 
P [ Z < Z1-a] = P [ Z < 1.64] = O. 
and 
P [ Z > Z1-a J = P [ Z > 1.64] = 0.20 
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Genotype frequencies for the dominant and recessive models: 
In genetics a trait is considered dominant, when it expresses a phenotypic 
effect with only one copy of the gene and it is considered recessive if a trait is 
expressed only if two copies of the gene are inherited. To illustrate, if we 
consider the gene BHMT (A742G), the population allele frequency for the major 
allele (A) and minor alleles (G) are 0.28 and 0.72 (1- 0.28= 0.72) respectively. If 
Hardy Weinberg equilibrium (p2 + 2pq + q2= 1) is applied: 
p2 = GG = (0.72)2= 0.52 
2pq = GA = 2 X 0.72 X 0.28= 0.40 
q2 = AA = (0.28)2= 0.08 
For the recessive model, 
GG + GA = 0.52 + 0.40 = 0.92 
AA= 0.08 
For the dominant model, 
GG= 0.52 
GA + AA= 0.40 + 0.08 = 0.48 
The following table shows the values of f and g corresponding to dominant and 
recessive model for all five SNPs in this study 
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Table 2: Values of f and 9 for dominant and recessive models 
RECESSIVE MODEL DOMINANT MODEL 
Gene Allele f 9 f 9 
freq 
BHMT 0.28 GGI 0.92 AA 0.08 GG 0.52 GAl 0.48 
(A742G) GA AA 
MTR 0.19 AAI 0.96 GG 0.04 AA 0.65 AGI 0.35 
(A275SG) AG GG 
MTRR 0.35 AAI 0.88 GG 0.12 AA 0.42 AGI 0.58 
(GSSA) AG GG 
SHMT1 0.26 AAI 0.93 GG 0.07 AA 0.55 AGI 0.45 
(G1420A) AG GG 
FOLR1 0.32 GGI 0.90 AA 0.10 GG 0.46 GAl 0.54 
(GSOSA) GA AA 
Power for overall and stratified (chemotherapy Vs no chemotherapy) 
models: 
For a one tailed test, by insert ing the values corresponding to BHMT gene in 
equation 2 (Z1-a= 1.64) , to detect a hazard ratio of 2.00 for a total of 107 deaths 
out of the 772 subjects enrolled in the study, we have: 
. Zl-P = -JDfg x log~ - Zl-a 
= ..)107 X 0.48 X O. 52 x log(2) - 1.64 
= 1.94 
So 1-~ = 0.974 which is 97.4% power 
For a two-sided test: 
= ..)107 X 0.48 X O. 52 x log (2) - 1.96 
= 1.62 
So 1-~ = 0.948 which is 94 .8% power. 
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Applying the same equation the results for all five SNPs are reported in table 3. 
Microsoft Excel 2010 was used to analyze powers to detect a hazard ratio of 
2.00, 1.75 and 1.50 for both two and one tailed tests. Power for stratified models 
(chemotherapy v. no chemotherapy) was also calculated for both two and one 
tailed tests and is shown in table 4. 
Table 3: Power (two and one-tailed) to test association between genotype 
and breast cancer mortality for the main effects of the dominant models 
using all three HEAL sites (N= 772) 
RECESSIVE MODEL DOMINANT MODEL 
Gene Allele HR HR HR HR HR HR 
freq 2.00 1.75 1.50 2.00 1.75 1.50 
Two- tailed test 
BHMT 0.28 1.00 0.99 0.95 0.95 0.82 0.55 
(A742G) 
MTR 0.19 0.9 0.21 0.13 0.93 0.79 0.52 
(A2756G) 
MTRR 0.35 0.64 0.47 0.28 0.94 0.82 0.54 
(G66A) 
SHMT1 0.26 0.45 0.32 0.19 0.95 0.82 0.55 
(G1420A) 
FOLR1 0.32 0.58 0.41 0.24 0.95 0.82 0.55 
(G606A) 
One-tailed test 
BHMT 0.28 1.00 1.00 0.98 0.97 0.89 0.68 
(A742G) 
MTR 0.19 0.41 0.30 0.21 0.96 0.87 0.64 
(A2756G) 
MTRR 0.35 0.76 0.59 0.39 0.97 0.89 0.67 
(G66A) 
SHMT1 0.26 0.58 0.44 0.28 0.97 0.89 0.67 
(G1420A) 
FOLR1 0.32 0.69 0.54 0.35 0.97 0.89 0.67 
(G606A) 
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Table 4: Power (two and one-taifed) to tesl3ssociation between genotype llnd bre<'lst c;ancer mortality for the 
dominant models sV"tified by lise of ch~motherapy using all three HEAL sites 
~r<:E SSI"!: M(')(5£:L (5(')MlNAN'f M(')(5E'l 
Gene Allele ChelTlotMrapy Ro Chemodi~rapy Chemotherapy No CMmotherapy 
rceQ (N- 31$) (N" (57) (N .. 3151 (N- 457) 
HR HR HR HR HR HR HR HR HR HR HR HR 
2.00 1.75 1.50 2.00 1.15 1.50 2.00 1.15 1.50 2.00 t .75 1.50 
Two-tailed lest 
BHMT 2& 099 {) 99 085 093 079 085 OSS 067 0 41 051 036 041 
(A142G) 
MTR 19 021 () 15 o 'to 0.12 009 010 031 () 63 038 048 034 038 
(A2756G) 
MTRR 3S o .!9 035 j) 20 025 018: {) 20 () 8.! 066 04 1 050 035 O;! , 
(G66A} 
SHMT1 26 o 3:r- 023 014 017 0.13 014 084 067 041 051 036 041 
(G1420A) 
FOLR1 32 o <!3 () 30 018 022 016 o is o S ~ 067 O.l 1 OS 1 036 0 ')1 
(G60M)' 
.,. One-tailed lest 
IJ1 8HMT 23 100 '0 '99 091 096 087 064 0.91 I) 78 054 064 0 49 on 
(A742G} 
MTR 19 (132 024 0.17 _. 019 015 012 089 0.14 051 060 046 029 
(A2.7S6G) 
MTRR 35 062 0 :.7 () 31 037 028 019 090 on 053 063 0 48 03 1 
(G6&A) 
SHMT1 i6 045 034 023 QU 021 {l1S 0.91 018 0504 063 OAS 0,3'2 
(G142C1A) 
-- --
FOLR1 J2 056 <) 42 028 on 025 017 091 a 1a 054 064 0 49 03 
(G606A) 
If the calculations are restricted to samples from the New Mexico site only, power 
for the main effect and stratified models (chemotherapy v. no chemotherapy) for 
both two and one-tailed tests are shown in Tables 5 and 6 respectively. 
Table 5: Power (two and one-tailed) to test association between genotype 
and breast cancer mortality for the main effects of the dominant models 
using samples from New Mexico site (N= 446) 
RECESSIVE MODEL DOMINANT MODEL 
Gene Allele HR HR HR HR HR HR 
freq 2.00 1.75 1.50 2.00 1.75 1.50 
Two- tailed test 
BHMT 0.28 0.97 0.87 0.61 0.60 0.43 0.25 
(A742G) 
MTR 0.19 0.14 0.10 0.07 0.56 0.40 0.24 
(A2756G) 
MTRR 0.35 0.30 0.21 0.13 0.59 0.42 0.25 
(G66A) 
SHMT1 0.26 0.20 0.15 0.09 0.59 0.43 0.25 
(G1420A) 
FOLR1 0.32 0.26 0.19 0.12 0.59 0.43 0.25 
(G606A) 
One-tailed test 
BHMT 0.28 0.99 0.92 0.72 0.72 0.56 0.37 
(A742G) 
MTR 0.19 0.22 0.17 0.13 0.68 0.53 0.34 
(A2756G) 
MTRR 0.35 0.42 0.32 0.21 0.71 0.55 0.36 
(G66A) 
SHMT1 0.26 0.30 0.23 0.16 0.72 0.56 0.36 
(G1420A) 
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Limitations of the power analysis: 
For the purpose of this study, however, a one tailed test is used for the following 
reasons: 
.:. Due to limited current literature on the association between the genes in 
the folate metabolizing pathway and breast cancer survival, the direction 
of the associations could not be determined a priori . 
• :. A one sided test has greater power over a two-sided non-directional test 
Power analysis was based on the entire HEAL cohort based on data from the 
preliminary investigation of the two polymorphs corresponding to the MTHFR 
gene (Chapter IV). The preliminary study included biological specimens from all 
three sites collected during baseline interview. Samples diagnosed with in situ 
tumors were excluded from the study (refer to Chapter IV for exclusion criteria). 
But for studying the association between the SNPs corresponding to BHMT, 
MTR, MTRR, SHMT1, and FOLR1 and breast cancer mortality only the samples 
from New Mexico site were available. Blood specimens collected during both 
baseline and 24 months follow-up interviews were used for genotyping of these 
SNPs. 
GENOTYPING 
For the New Mexico site, 30mL of blood was collected from women who 
consented to provide biological specimens at baseline and 24 month follow-up 
visits. The blood samples were processed and stored at - 70 to - 80°C within 3 
hours of collection. DNA was isolated from stored buffy coat using Purogene 
(Gentra Systems, Inc.) extraction kits .. A StepOnePlus real-time polymerase 
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chain reaction (RT-PCR) system (Applied Biosystems by Life Technologies 
Corporations) was used to genotype the five SNPs under investigation. The RT-
PCR was factory calibrated to generate accurate outputs with 99.7% 
confidence 110. TaqMan SNP genotyping assays were used consisting of two 
PCR primers specific to the locus under investigation and two oligonucleotide 
probes specific to the allele of interest. Each probe has fluorescent dye, FAM 
and VIC at the 5' end and a non-fluorescent quencher with a minor groove binder 
(MGB) at the 3' end 111 . The major allele of a SNP was identified by the FAM dye 
while the minor allele was identified by the VIC dye. A reaction cocktail of 1 0 ~L 
of 2X master mix, 0.5 ~L 40X assay, and 4.5 ~L of de-ionized water was used 
with required amounts of DNA-TE mixture to initiate each RT-PCR reaction. 
During each RT-PCR cycle, the probe, which was hydrolyzed to the allele of 
interest, emitted a fluorescent signal when it cleaved to the 5' exonuclease action 
of the AmpliTaq Gold DNA Polymerase. The primers amplified the locus of 
interest in the DNA template and the dye specific to the alleles reported the 
presence or absence of the allele in the DNA sample112113. The presence of two 
probes, each specific to an allele of the SNP under investigation and labeled with 
two dyes, enabled two alleles to be detected in a single tUbe 113. Appendix III 
provides the details of the genotyping procedure. 
After genotyping was completed, results were tested for the Hardy 
Weinberg Equilibrium (p2 + 2pq + q2 = 1). Table 7 shows the calculations for the 
Hardy Weinberg Equilibrium in this study. There was significant difference 
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between the observed and the expected frequencies as is reflected in the chi 
square p values. 
Table 7: Calculations for Hardy Weinberg Equilibrium for the SNPs 
investigated in this study 
Genes Obs Obs Obs Exp Exp Exp P q Chi-sq 
AA AB BB AA AB BB P value 
BHMT 204 198 44 205.8 194.3 45.8 0.679 0.321 0.92 
MTR 280 138 25 274.9 148.1 19.9 0.788 0.212 0.35 
MTRR 104 216 121 101.9 220.2 118.9 0.481 0.519 0.92 
SHMT 211 194 38 214.1 187.7 41 .1 0.695 0.305 0.78 
FOLR 210 187 48 206.9 193.0 44.9 0.682 0.318 0.81 
Obs AA: observed homozygous wild-type ; Obs AB: observed heterozygous; Obs BB: observed 
homozygous variant; Exp AA: expected homozygous wild-type; Exp AB: expected heterozygous; 




MTHFR POL YMORPHISMS AND BREAST CANCER SURVIVAL 
INTRODUCTION 
The preliminary investigation reports results from the analyses of the 
associations between the C677T and A 1298C MTHFR polymorph isms with 
breast cancer-specific survival and how chemotherapy modifies the effect of the 
polymorph isms on survival using data from the HEAL Study. 
MATERIALS AND METHODS 
Statistical methods 
Cox Proportional Hazard analysis was applied to compare the effect of 
MTHFR polymorph isms on women who received chemotherapy and those who 
did not receive chemotherapy on three outcomes: all-cause mortality and breast 
cancer-specific mortality. Analyses adjusted for relevant covariates including 
stage at diagnosis, ER-status, menopausal status, site, race, BMI, tamoxifen use, 
and family history of BC. Because race and site were highly correlated, site was 
included in the final model. Menopausal status, BMI, tamoxifen use and family 
history of BC did not influence the effect estimates and were not included in the 
final model. Univariate models for the two MTHFR polymorph isms, 
chemotherapy use, stage at diagnosis, ER-status and site were constructed for 
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the three outcomes. Since stage at diagnosis, ER-status and chemotherapy are 
highly correlated, only chemotherapy was used in the final model. Multivariate 
models tested for interactions between the variant alleles and chemotherapy. 
Chemotherapy was stratified into two categories based on folate-dependence 
and used in multivariate models. Diplotype and compound homozygous and 
heterozygous models were created to test if the effect of combined genotype 
modifies chemotherapy use on the three outcomes. 
RESULTS 
Below is a diagrammatic representation of the cohort. Also shown in the 
figure is the number of all-cause and breast cancer specific deaths stratified by 
chemotherapy. Only subjects diagnosed with invasive tumors with biological 
specimens were used in the analysis. 
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./ 
Figure 9 Health, Eating, Activity, and Lifestyle (HEAL) cohort definition and 
number of events during 10 years of follow-up stratified by chemotherapy 
Figure 9 shows the distribution of relevant demographic, genotype and clinical 
characteristics for the cohort stratified by treatment with chemotherapy (yes, no) . 
Fifty-four percent of the participants were non-Hispanic white , 31 % African 
American and 13% Hispanic. Sixty-two percent were post-menopausal , and 35% 
were overweight or obese. Forty-eight percent had the T allele (CTITT) for 
C677T and 45% had the C allele (AC/CC) for A 1298C. Those who received 
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chemotherapy tended to be African American , younger, premenopausal women 
with more advanced disease and ER negative tumors at diagnosis . 
Table 8: Demographic and medical characteristics of breast cancer 
survivors (N= 772) in the Health, Eating, Activity, and Lifestyle study 1 
No X2 
Descriptive Chemotherapy C hemothera py P-value 
Characteristics N=457 % N=315 % 
Genotype 
C677T 0.137 
CC 229 50 175 56 
CT/TT 228 50 140 44 
A1298C 0.291 
AA 245 54 181 57 
AC/CC 212 46 134 53 
Age at Diagnosis2 58.3 11.41 49 .2 8.22 
Body Mass Index 0.333 
(Kg/m 2) 283 62 213 68 
Normal « 25.0) 99 22 57 18 
Over weight (25.0-29.9) 70 15 45 14 
Obese (>=30) 
Study site <0.001 
New Mexico 288 63 118 37 
Seattle 64 14 63 20 
Los Angeles 105 23 134 43 
Race <0.001 
Hispanic 61 13 37 12 
Non-Hispanic white 281 61 135 .43 
African American 105 23 134 43 
Other 10 3 9 2 
Menopausal Status <0.001 
Pre-menopause 113 26 158 54 
Post-menopause 317 74 133 46 
Breast cancer stage <0.001 
Localized 401 88 134 43 
Regional 54 12 181 57 
ER Status <0 .001 
Positive 345 87 168 57 
Negative 53 13 125 43 
PR Status <0.001 
Positive 267 73 142 53 
Negative . 97 27 128 47 
'Cell size may vary because of missing values. Only participants in the HEAL study diagnosed with invasive tumor and 
with available DNA from the 24-months interview were used in the analysis; 2 mean ± SD 
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Table 9 shows that carriers of the variant alleles of both C667T and 
A 1298C polymorphisms, had lower breast cancer mortality compared to the 
homozygous wild-type (C677T: HR= 0.76,95 % CI: 0.51 , 1.11; A1298C: HR= 
0.71 , 95 % CI: 0.48 , 1.05). 
Table 9: Crude Hazard Ratios for any cause mortality and breast cancer-
specific mortality for study variables (11.46 years) 
ALL CAUSE MORTALITY BREAST CANCER-SPECIFIC 
MORTALITY 
Variables Deaths Hazard P- Deaths Hazard P-
N % Ratio value N % Ratio value 
95%CI 95%CI 
C677T 
CC 96 55 1.00 63 59 1.00 
CT/TT 79 45 0.89 0.45 44 41 0.76 0.15 
0.66-1.20 0.5-1.10 
A1298C 
AA 105 60 1.00 67 63 1.00 
AC/CC 70 40 0.79 0.13 40 37 0.71 0.08 
0.59-1 .07 0.48-1 .05 
Chemo 
thera~y 85 49 1.00 33 31 1.00 
No 90 51 1.66 <0.01 74 69 3.48 <0.01 
Yes 1.23-2 .23 2.31-5.25 
-Information on ER-status and stage at diagnosis was not available for all subjects 
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Table 10 Prognosis: stratified by chemotherapy and genotype showing breast cancer mortality 
Hazard Hazard Hazard 
Chemo Genotype Deaths Ratio P. Deaths Ratio p. Deaths Ratio P. 
theraey N % 95% CI value N % 95%CI value N 0/" 95%CI value 
C677T FIVE YEARS SEVEN YEARS TEN YEARS 
CC 11 12 Reference 11 11 Reference 16 15 Reference 
No cTin 16 18 224 006 16 16 226 005 17 16 158 023 
097·5.17 098-5.22 075-3.34-
CC 40 45 Reference 46 46 Reference 47 44- Reference 
Yes cTin 22 25 0.75 0.32 24 25 0.70 0.19 27 2S 0.78 0.34 
0.43·1 .31 0.42-1 .19 0.47-1.29 
A1298C FIVE YEARS SEVEN YEARS TEN YEARS 
AA 18 20 Reference 18 19 Reference 21 22 Reference 
No AGCC 9- 10 0.65 0.31 9 9 064- 0.29 12 12 0.76 0.49 
0.26-1 49 028-1.47 0.37-1.63 
AA 39 44 Reference 44 45 Reference 46 47 Reference 
Yes AClCC 23 26 0.82 046 26 27 082 043 28 29 066 052 
049·' 39 050-1 34 053-1 38 U1 
'Adjusted for age at diagnosis and race Stage al diagnosis and ER status are not adjusted form the model due IOSlrong en 
correlation with chemotherapy 
Table 11: Interaction of genotype with chemotherapy on breast cancer mortality 
Treatment C677T A1298C 
CC CTfTT AA ACfCC 
FIVE Deaths Hazard p. DeathS Hazard p. Deaths Hazard p- Deaths Hazard p -
YEARS Rallo value Ratio value Ratio vaHle Ratio value 
N 0/0 95% CI N Dj , I) 95 ~o CI N % 95% CI N % 95% CI 
No 11 12 Reference 16 18 1.73 0.17 18 20 Reference 9 10 0.67 
Chemotherapy 0.19-3.81 029-1..52 0,34 
Chemotherapy 40 45 4.76 22 25 3.99 39 44 327 23 25 2.62 
2.39-9.46 <0.01 1.S9-S .114 <0.01 1.82-5 .89 <0.01 1.39-4.93 ,<:0.01 
prOf Ihe 0.13 0.72 
interaction 
SEVEN Deaths Ha!ard p- Deaths Hazard p - Deaths Hazard p. Deaths Hazard p. 
YEARS Ratio value Ratio value Ratio value Ratio value 
N % 95%. CI N '1!~ 95% CI N % 95% CI N % 95% CI 
No 11 11 Reference 16 16 1.73 18 19 Reference 9 9 0.67 
Chemotherapy 0.79· 3.80 0.17 0.29· 1.51 0.33 
Chemotherapy 46 H 539 24 25 4.18 44 45 357 26 27 286 
27 4- <0 01 200-872 <0.01 201-634 <0,01 154·528 <001 
Lr1 10.59 
-....J 
PfOf the 0.08 0.71 
interaclion 
TEN Deaths Hazard p - Deaths Hazard p- Deaths Hazard p . Deaths Hazard p . 
YEARS Ratio va lue Ratio value Ratio value Ratio va lue 
N % 95%CI N ~'~ 95% CI N °/5 95% CI N %. 95% CI 
No 1615 Reference 17 16 ' .29 21 22 Reference 12 12 0.78 
Chemotherapy 0.64-2.59 OAS 0.38-1 .60 0,49 
Chemotherapy 47 4"; 3.77 27 25 3.25 46 47 3.13 28 29 263 
209·6.76 <0 01 1 71-6,17 <0.01 1.82· <001 147·4.69 <0 01 
5.37 
pror the 0.37 0.95 
interaction 
''Adjusted tor age at (hagnoS1S M d race. 
Table 10 shows results for analyses of the interaction of the variant alleles in 
C677T and A 1298T with chemotherapy by duration of follow-up, adjusting for 
age, study site, race, stage of disease and ER status. In a multiplicative model, 
in the absence of interaction the expected HR for those with the minor allele 
(CTITT or AC/CC) who received chemotherapy should be approximately equal to 
the HR for those with minor allele who did not received chemotherapy multiplied 
by the HR for the homozygous wild-type (CC or AA) group who received 
chemotherapy. The results, however, suggest antagonistic, multiplicative 
interaction between the T allele of C677T and chemotherapy because the 
observed HR for their joint presence is substantially less than expected. For 
example, for 7 years of follow-up, the expected result should be 1.18 (HR for 
CTITT not receiving chemotherapy) x 3.33 (HR for CC receiving chemotherapy) 
= 3.93 (HRexp for CTITT receiving chemotherapy). The observed HR, however, 
is 2.51, or 30% less than the expected result, and the formal test of interaction 
also approaches statistical significance (p = 0.09). The results in Table 11 also 
suggest that the interaction between the C677T polymorphism and 
chemotherapy is stronger during the first 5 to 7 years and attenuates somewhat 
thereafter. This is reflected in the p-values for interaction as well as in 
comparison of the expected to observed HRs for the joint effect group; for 
example the expected HR for CTITT and chemotherapy at 10 years is 4.86 
compared to the observed value of 3.25. We also computed an interaction 
model for C677T with chemotherapy without adjustment for stage of disease and 
ER status. While the absolute magnitudes of the HRs were larger across all 
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strata, the relative size of the interaction was similar (the observed HR was 
approximately 45% less than the expected value). In contrast to C677T, there 
was no evidence whatsoever for interaction between A 1298C and chemotherapy 
at 5, 7 or 10 years of follow-up. 
Because stage of disease and ER status are criteria used by clinical 
oncologists to assign breast cancer patients to receive chemotherapy rather than 
hormonal therapy, the possibility exists for residual confounding of the interaction 
between C677T and chemotherapy by these prognostic factors. As a result, we 
also explored the interactions of the MTHFR polymorph isms with stage of 
disease (local versus regional) and ER (negative versus positive) independent of 
chemotherapy. None of the interactions were statistically significant or 
approached significance (p's > 0.40; Hazard Ratios not shown) for at 5, 7 or 10 
years of follow-up. Once again, there was no evidence for interaction between 
the A 1298C polymorphism and either stage of disease or ER status on breast 
cancer mortality. 
The Kaplan Meier graphs shown in Figures 10 and 11 provide additional 
evidence for an interaction between C677T and chemotherapy. The difference 
between chemotherapy and no chemotherapy groups is visibly greater in the 
women with the CC genotype than in those with CTrrT genotypes, or T allele. 
To further investigate the effect of chemotherapy on breast cancer-
specific, chemotherapy was stratified based on folate dependence (folate 
depleting chemotherapy (170 (54%)) versus non-folate depleting chemotherapy 
(145(46%)) and adjusted for relevant covariates. No significant change in hazard 
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ratios were observed (C677T: HR= 1.75 , 95% CI : 0.79, 3.84; A 1298C: HR=0.63 , 
95% CI: 0.28 , 1.42). 
Figure 10: Kaplan-Meier curve for ten years breast cancer-specific mortality 
by chemotherapy for carriers of CC genotype (C677T polymorphism) 
showing number of months from diagnosis to breast cancer death using 
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Figure 11: Kaplan-Meier curve for ten years breast cancer-specific mortality 
by chemotherapy for carriers of CTITT genotype (C677T polymorphism) 
showing number of months from diagnosis to breast cancer death using 
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Figure 12: Kaplan-Meier curve for ten years breast cancer-specific mortality 
for carriers of A 1298C polymorphism showing number of months from 
diagnosis to breast cancer death using data from Health, Eating, Activity, 
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The results of this investigation suggest that carriers of the variant alleles 
of both the C677T and A 1298C MTHFR polymorphisms may be protected 
against breast cancer mortality. Our results additionally suggest that the C677T 
polymorphism may modify breast cancer survival in women receiving 
chemotherapy. While formal tests of statistical significance for both main effects 
and interactions of these MTHFR polymorph isms with chemotherapy were not 
significant due the small sample size (n = 772) , the effect sizes observed are 
potentially, clinically meaningful and should be replicated in larger cohort studies 
or clinical trials . These polymorph isms have been established to modify folate 
metabolism, which is important for DNA methylation and repair, and have been 
previously reported to be associated with breast cancer survival as well as breast 
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cancer risk 11-17. Because common chemotherapeutic agents used in breast 
cancer, such as MTX and 5FU, also impact folate metabolism, we hypothesized 
that these polymorph isms might also modify the efficacy of these drugs. 
Biochemical studies have shown that besides being an anti-metabolite of 
folate, two metabolites of 5-FU, 5-fluoro-2' -deoxyuridine-5 '-triphosphate and 5'-
flurouridine-5'-triphosphate when incorporated into DNA and RNA respectively 
could interfere with the level of DNA stability and RNA functioning6o . Again, 5'-
formylTHF, the precursor of 5, 10-methyleneTHF potentiates the cytotoxic effects 
of 5-FU by stabilizing the inhibition of 5, 10-methyleneTHF-TS- 5FdUMP 
complex. Studies have shown that the MTHFR polymorph isms that increases the 
concentration of 5, 10 -methyleneTHF may result in elevation the cytotoxic levels 
of 5FU60. Conversely, MTHFR polymorph isms that increases accumulation of 
5,10 -metheleneTHF is shown to alter the cytotoxic effects of MTX61. MTX 
inhibits dihydrofolate reductase, decreases intracellular 5,10 -methyleneTHF 
levels for the synthesis of thymidylate and inhibits the synthesis of purine61 . In 
short, these chemotherapeutic agents affect DNA synthesis and intimately down-
regulate cell replication. In fact, experimental studies investigating the 
relationship between MTHFR polymorph isms and commonly used 
chemotherapeutic agents on breast cancer cell lines 2324, mice models 24 and 
breast cancer patients 2025-27 have shown that MTHFR polymorph isms influences 
the concentration and cellular pathway of folate metabolism altering their 
chemosensitivity. 
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The results suggest that the C677T polymorphism may modify the effects 
of chemotherapeutic treatment. This interpretation is supported by the following 
arguments. The presence of the T allele for C677T was not associated stage at 
diagnosis or ER status, and the interaction with chemotherapy was not 
meaningfully diminished by adjusting for these covariates of chemotherapy. 
Moreover, it is difficult to see how the T allele might modify the associations of 
these prognostic variables with subsequent survival because they are fixed 
characteristics established at the time of diagnosis. Adjusting for these variables 
diminished the absolute values of the HRs, but did not affect the relative strength 
of interaction, indicating confounding between chemotherapy and these 
prognostic characteristics. Thus, the better than expected survival of women 
receiving chemotherapy who have the T allele may reflect a modification of the 
effectiveness of chemotherapeutic treatment. Once again, the plausibility of this 
interpretation is supported by the fact that the women receiving chemotherapy 
were predominantly taking methotrexate and/or 5FU, which are known to affect 
folate metabolism. 
The data suggests that there is no correlation between the C677T and 
chemotherapy (Pearson correlation coefficient; r = -0.003), so it may support the 
notion that the variant allele of the C677T alter the metabolism of the 
chemotherapeutic drug, reducing the probability of adverse events or may reduce 
the side effects of the drug, thus contributing to decrease in breast cancer 
mortality among carriers of the T allele compared to those not carrying the T 
allele. The direct association of A1298C, on the other hand, suggests protection 
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against breast cancer mortality, even after adjusting for established prognostic 
markers of breast cancer. A 1298C may influence breast cancer survival through 
a different pathway from C677T. 
To test the association between the two polymorph isms and breast 
cancer-specific mortality we performed diplotype analysis. The results of the 
diplotype analysis or compound genotype analysis suggest although 
recombination between the variant alleles of the two polymorph isms was rare 
(CTAC; n= 130, TTAC; n= 3, TTCC; n=O) (figure 12). There was strong linkage 
disequilibrium between the two polymorph isms (Lewontin's 0' = 0.94) suggesting 
that the two polymorphisms may be associated with breast cancer survival in two 
different ancestral pathways. The fact that there was no correlation (0.001) 







Figure 12 Patterns of recombination showing change in C677T and A1298C 
polymorph isms 
Although no correlation among the polymorph isms and ER-status, and 
stage at diagnosis was observed, there were strong correlations among both 
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covariates and chemotherapy because they are significant prognostic markers of 
breast cancer and are important deciding factors in chemotherapeutic regimen. 
Both ER-status and stage at diagnosis may, therefore, be mediators of the 
relationship between genotype and chemotherapy. The notion is further 
supported by the results of the univariate analyses which show approximately 
three times higher breast cancer-specific mortality rates for all three variables. 
Both covariates were, therefore, not adjusted in our mUltivariate models. The 
effects of ER-status and stage at diagnosis were investigated in this study. Unlike 
the results of Long Island Breast Cancer Studi 9 and Shanghai Breast Cancer 
StudlO which suggested that ER-status modified the effect of C677T and breast 
cancer survival and C677T significantly increased the survival of women 
diagnosed with late stage (stage III-IV) tumor respectively, no such interactions 





The current chapter describes the findings of the dissertation. In all the 
tables in this chapter the two polymorph isms of MTHFR are also listed along with 
the five genes investigated in this dissertation project. The purpose of having the 
two MTHFR polymorph isms was to compare the findings of this analysis based 
on samples from the New Mexico site with findings based on an earlier analysis 
using all available samples from the three HEAL study sites (see Chapter IV), 
and (b) to test for gene-gene interaction between the MTHFR polymorph isms 
and breast cancer-specific mortality. 
DESCRIPTIVE STATISTICS 
Out of the 446 women in the New Mexico site, a total of 67 (15%) were 
deceased as of 12/31/2007 at 11.46 years; 22 (5%) deaths were due to breast 
cancer for women diagnosed with invasive disease. More than three-fourths 
(78%) of the participants were non-Hispanic white, 22% were Hispanic and 3% 
belonged to the other category. The majority of the participants were normal 
(43%; 8MI: 18.5-24.9) or over-weight (31 %; 8MI: 25.0-29.9), 8% were below 
normal (8MI: <18.5) and 18% were obese (8MI: >=30). Sixty-eight percent of the 
sample was post-menopausal and 32 % were pre-menopausal. More than half 
of the participants were diagnosed with a localized tumor (62%), 18% were 
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diagnosed with regional tumor and 20% with in situ beast disease. Table 12 
describes the demographic and medical characteristics of the participants (N= 
446) in the New Mexico site and table 13 provides the frequency distribution of 
the genotypes of the breast cancer survivors. 
Table 12: Demographic and medical characteristics of breast cancer · 
survivors for the New Mexico site in the Health, Eating, Activity, and 
Lifestyle Study (n= 446)1 
Descriptive Characteristics Breast Cancer Total 
Deaths N %/SD 
Age at Diagnosis (yrs)2 22 57.6 12.1 
Race3 22 
Hispanic 97 22 
Non-Hispanic white 346 78 
Body Mass Index (Kg/m2)4 22 
Below normal «18.5) 37 8 
Normal (18.5-24.9) 190 43 
Over weight (25.0-29.9) 137 31 
Obese (>=30) 78 18 
Menopausal Status 22 
Pre-menopause 136 32 
Post-menopause 294 68 
Stage at Diagnosis 22 
In situ 89 20 
Localized 276 62 
Regional 81 18 
Estrogen Receptor Status5 17 
Positive 257 82 
Negative 56 18 
Progesterone Receptors Status6 18 
Positive 213 71 
Negative 89 29 
Chemotherapy 22 
No 334 75 
Yes 112 25 
Tamoxifen use 22 
No 242 54 
Yes 204 46 
Oral Contraceptive Use7 22 
No 160 36 
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Yes 
Hormone replacement Therapy? 
No 
Yes 







Total Folate Intake (lJg)10 
Vitamins (mg/d)10 
Total B1(Thiamin) 
Total B2 (Riboflavin) 
Total B3 (Niacin) 
Total B6 (pyridoxine, pyridoxal , & 
pyridoxamine) 































Alcohol (gm/day)10 20 4.3 9.7 
Energy Intake (kcalfo 20 1401.3611 
' Percentages calculation excludes missing values; 2 mean ± SO; 3 other in race : 3; 4 missing 
values in 8MI : 4; 5 missing values in ER-status: 133; 6 missing values in PR-status: 144; 7 missing 
values in OC and HRT use: 1; 8 missing values in family history of breast cancer: 35; 9 missing 
values among current smoker: 197; 10 missing values in energy intake, vitamins , folate and 
alcohol intake: 14. 
Table 13: Genotypes of breast cancer survivors for the New Mexico site in 
the Health, Eating, Activity, and Lifestyle Study (n= 446) 
Genotypes 































MTRR (N= 441 ; rs1801394) 
G66A 21 0.92 
GG 104 24 
AG 216 50 
AA 121 27 
GAlAA 307 76 
SHMT1 (N= 443; rs1979277) 
C1420TI G1420A 22 0.78 
GG 211 48 
AG 194 44 
AA 38 9 
GA/AA 232 52 
FOLR1 (N= 445; rs3796517) 
G606A 22 0.80 
GG 210 47 
AG 187 42 
AA 48 11 
GAlAA 235 53 
MTHFR(N= 397; rs1801133) 
C677T 20 0.96 
CC 165 42 
CT 184 46 
TT 48 12 
CTrrT 232 58 
MTHFR(N= 397; rs1801131) 
A1298C 20 0.99 
AA 197 50 
AC 165 42 
CC 35 8 
AC/CC 200 50 
'Abbriviation: HWE: Hardy Weinberg Equilibrium. 
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AIM 1: MAIN EFFECTS 
The associations between the genes in the folate metabolizing pathway 
and all-cause and breast cancer-specific mortality are summarized in table 14. 
All models reported in table 14 were adjusted for age. Adjustments for the 
potential confounders, race/ethnicity, menopausal status, BMI, stage at 
diagnosis, treatment types, ER status, folate, B-vitamin intake, and alcohol intake 
did not change the point estimates by more than 10%. 
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Table 14 Age..adjusted hazard fattos t and 95% confidence intervals for the associations of polymorphisms in the 
folate metabolizing pathway and all -cause mortality and breast cancer .specific mortality using data from the New 
Mexico site of the Health , Eating, Activity, and Lifestyle study (N= 446). 
All .CAUSE MORTALITY BR-EA-S-r-O'U'fCER=SPEtlFIC--';KfRTAnrV 
Genotypes Deaths Censored HR (99/0 CI) P Deaths Censored HR (95% Cl) P 
N N % value N N % value 
BHMT (N= 446) 
A742G 
AA 30 174 85 1 00 8 196 96 1 00 
AG 26 172 87 098 06·1 7 0.93 12 189 94 1 52 o 6-3 7 036 
GG 11 33 75 1 61 08-32 018 2 42 95 1 17 o 3-5 5 084 
AGfGG 37 205 85 1 10 o 1-1 8 089 14 228 94 1 45 o 6-3 5 039 
MTR lN~M3l .. '-.J 
~ A2756G 
AA 4.2 238 85 1.00 14 266 95 1.00 
AG 21 117 85 1 19 07-20 0.52 6 132 96 082 03-2.1 082 
GG 3 22 a8 079 0.3-2.6 0.69 1 24 96 082 0.1-6.2 0.85 
AGJGG 24 139 85 1. 12 O . 7~1 .9 0.67 7 156 96 0.82 0.3-2.0 067 
. MTRR tN .. 441) .. ,. 
GS6A 
GG 27 9.1 78 1 00 10 111 92 1 00 
GA 28 188 87 052 o 3-0 9 001 7 209 97 038 02-1 0 005 
AA 11 93 89 047 o 2-0 9 003 J 100 % 0 -12 o ,., 4 o 15 
CAlM 39 281 88 0.51 o 3-0.8 <001 11 309 97 O·tO o 2-0 9 o OJ. 
• SHMT1(N= 443) 
G1420A 
GG 35 176 83 tOO 10 201 95 1 00 
AG 29 165 85 0.93 06·1.5 078 11 183 94 1.17 0.5-28 0.71 
AA 3 35 92 057 o 2·1 .9 0.35 1 37 97 051 0.1·3.9 0.52 
GAlAA 32 200 86 087 05-14 0.57 12 220 95 1 06 05-25 089 
' AdJustl1'1g lo(chnrcal covanates stage at dIagnOSIs. ChemotheraP'1 use, ER·stalusdld not alfect POUlt estimates by more thal1 'O .,~ 
Table 14 continued: Age-adjusted hazard ratios t and 95%) confidence intervals forthe associations of 
polymorphisms in folate metabolizing pathway and all-e3use mortality and breast cancer-specific mortality using 
data from the New Mexico site of the Health, Eating, Activity. and Lifestyle study (N'" 446). 
ALL-CAUSE MORTALITY 8REAST CANCER-SPECIFIC MORTALITY 
Genotypes Deaths ·Censored HR (95% CI) P Deaths Censored HR (95'7'0 CI) P 
N N % value N N % value 
FOLR1(N= 446) 
G606A 
GG 27 183 67 1 00 9 201 96 1 00 
AG 32 155 83 1.26 0.8-2.1 0.38 8 179 96 1 02 0.4-2.7 0.96 
AA 8 40 83 108 05-2 4 084 5 43 90 2.51 0.8-7.5 o 10 
GAl.A.A 40 195 83 1 22 0.8-1 .9 042 13 222 95 1.33 0.6-3.1 052 
MTHFR(N= 397)2 
-...J C677T 
N CC 22 143 87 1.00 5 160 97 1.00 
CT 26 158 86 0.98 06-1 7 0.94 12 172 93 222 0.8-63 0.13 
TT 9 39 81 1.56 0.7-3.4 0.27 3 45 94 2.14 0,5-8.9 0.29 
CTllT 35 197 85 1.08 06-1.8 0.78 15 217 94 2. 17 0.8-5.9 0.13 
MTHFR(N;; 397)( 
A1298C 
AA 29 168 85 1 00 10 187 95 1 00 
AC 23 142 85 0.89 a 5-1.5 067 10 155 94 1.19 0.5-2 .9 069 
CC 5 30 86 089 o 3-2.3 081 0 35 100 NJA 
ACICC 28 172 86 0.88 0.5-1.5 0.62 10 190 95 0.98 0.4-2.4- 0.97 
'Adjust ing foreliniesl covariates stage at diagnosis, ehemotheraP'1 use. ER·sr3tus did not affect point estimates by more than 10%: 
' Only baseline DNA included in the analyses. 
There was a statistically significant inverse association between the 
MTRR G66A polymorphism and breast cancer-specific mortality: carriers of the 
variant alleles (GA/AA) had reduced risk compared to carriers of the homozygous 
wild-type genotype (GG) (HR: 0.40; 95% CI: 0.2-0.9; P- value: 0.04). The 
association remained statistically significant when the heterozygous GA (HR: 
0.38; 95% CI: 0.2-1.0; P-value: 0.05) and homozygous AA (HR: 0.42; 95% CI: 
0.1-1.4; P-value: 0.15) were compared to the GG genotype. Similar significant 
inverse associations were also observed between carriers of the variant alleles of 
the MTRR G66A polymorphism and all-cause mortality compared to carriers of 
the homozygous dominant genotype. 
A non-significant, positive association was observed between the MTHFR 
C677T polymorphism and breast cancer-specific mortality: carriers of the variant 
allele (CTITT) had increased risk compared to the women who were 
homozygous for the major allele (CC) (HR: 2.17; 95% CI: 0.8-5.9; p- value: 0.13). 
This positive trend for association also was evident when the heterozygous CT 
(HR: 2.22; 95% CI: 0.8-6.3; p- value: 0.13) and homozygous n (HR: 2.14; 95% 
CI: 0.5-8.9; p- value: 0.29) genotypes were separately compared to the CC 
referent group. Although there was no association between carriers of CT 
genotype and all-cause mortality, there was a positive association among 
carriers of homozygous n genotype and all-causes mortality (HR: 1.56; 95% CI: 
0.7-3.4; p- value: 0.27). 
A non-significant, inverse association with breast cancer mortality also 
was observed among carriers of the variant allele (G) of the MTR A2756G 
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polymorphism. No consistent association was, observed for all-cause mortality 
and MTR A2756G genotype. The three other SNPs, BHMT A742G, SHMT1 
G1420A, and FOLR1 G606A, were not statistically, significantly associated with 
either breast cancer-specific or all-cause mortality in this sample (table 14). 
Test for confounding: 
To explore if demographic and clinical covariates such as race/ethnicity, 
8MI, menopausal status, stage at diagnosis, chemotherapy, ER-status 
confounded the associations between the genes in the folate metabolizing 
pathway and breast cancer-specific mortality, multivariate Cox proportional 
hazard analysis models were tested. Models with covariates including dietary 
intakes of folate and 8 complex vitamins, smoking status and alcohol 
consumption were examined. Age-adjusted HRs reported in tables 14 did not 
change with the incorporation of these covariates of interest in the models. None 
of these covariates in multivariate Cox proportional hazard analysis models 
produced a change greater than 10% in the main effects of the SNPs. 
AIM 2: GENE - GENE INTERACTION 
Gene-gene interaction was significant for two interactions (BHMT A742G 
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'AdJustmg forclmlcal covanate3 stage afdlagnosis. chemotherapy use. ER. -status did not af~e,:t point estimates by more th3n 10%: 
'Only haseline DNA included in the analy~e!i. 
For the model examining interaction between BHMT A742G and FOLR1G60A, 
women with AA genotype for BHMT A742G and the GG genotype for FOLR1 
G606A were considered the referent group. Women with at least one variant 
allele for BHMT A742G (GA/GG) and FOLR1 G606A (GG) (HR: 0.44; 95% CI: 
0.1-1.8; p-value: 0.25) and those with the AA genotype for BHMT A742G and 
GA/AA for FOLR1 G606A (HR: 0.33; 95% CI: 0.1-1.6; p-value: 0.17) had an 
inverse association with breast cancer-specific mortality (Figures 13 and 14). 
Women with at least one variant allele for both FOLR1 G606A polymorphism 
(GA/AA) and BHMT A742G (AG/GG) had a positive association with breast 
cancer-specific mortality rates (HR: 1.42; 95% CI: 0.5-3.8; p-value: 0.49). The P 
value for interaction was 0.03. There was synergistic effect of the variant alleles 
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Figure 13: Kaplan-Meier survival curves among carriers of the BHMT 
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A742G, AA genotype stratified by FOLR1 G606A polymorphism, HEAL 
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Figure 14: Kaplan-Meier survival curves among carriers of the BHMT 
A742G, AG/GG genotype stratified by FOLR1 G606A polymorphism, HEAL 
study, New Mexico (N= 446) 
For the model investigating the interaction between MTRR G66A and 
MTHFR C677T, women carrying the genotypes GG for MTRR G66A and CTITT 
for MTHFR C677T were almost four times more likely to die due to breast cancer 
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(HR: 3.96; 95% CI: 1.2-13.2; p- value: 0.02) compared to women who were 
homozygous carriers of both major alleles (GG for MTRR G66A and CC for 
MTHFR C677T) (figure 15). There was non-significant inverse association with 
breast cancer-specific mortality for women carrying the genotypes GA/AA for 
MTRR G66A and CC for MTHFR C677T (figure 16). Non-significant associations 
were also observed for those with at least one variant genotype for both 
polymorph isms (GA/AA for MTRR G66A and CTITT for MTHFR C677T) 
compared to women with GG for MTRR G66A and CC for MTHFR C677T. In this 
multiplicative model P for interaction was 0.08. There was borderline antagonistic 
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Figure15: Kaplan-Meier survival curves among carriers of the MTRR G66A, 
GG genotype stratified by MTHFR C677T polymorphism, HEAL study, New 
Mexico (N= 446) 
MTH R {C677T) : CC 
1 a 
~ 
.D MTHFR (C677T) : CTtn 
ro 
.D 




~ P value: O. 7 
~ 
06 
0 2 4 6 s 10 12 
NO of years from date of diagnosis ' 0 death 
Figure 16: Kaplan-Meier survival curves among carriers of the MTRR G66A, 
GA/AA genotype stratified by MTHFR C677T polymorphism, HEAL study, 
New Mexico (N= 446) 
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AIM 3: GENE - ENVIRONMENT INTERACTION 
Interaction with chemotherapy: 
To explore if chemotherapy influences the effect of the genes in the folate 
metabolizing pathway on breast cancer-specific mortality, the associations 
between the polymorph isms and breast cancer mortality stratified by 
chemotherapy was examined in table 16. 
80 
Table 16: Age- adjusted breast «::ancer-spedfi'c mortality stratified by chemtOtoerapy and genotype in the New 
Mex.ico samples of the Hea.lth, Eatilllg. Acti vity, an d Li testyle Stu dy (n= 446). 
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Table 16 continued: Age- adjusted breast cancer-specific mortality stratified by chemotherapy and genotype in 
the New Mexico samples of the Health , Eating, Activity, and lifestyle Study (n= 446). 
Genotype Deaths Censored Hazard Ratio 1 p- Deaths Censored Hazard Ratio1 p -
N N % 95%CI value N N % 95%CI value 
No Chemotherapy Chemotherapy 
FOLR1 G606A (N= 445) 
GG 4 157 98 1.00 5 45 90 4.63 1.2-18.1 0.02 
GAlAA 4 169 98 0.89 0.2-3.6 0.87 9 53 85 7.07 2.0-24.5 <0.01 
PfOf 0,54 
teractio 
MTHFR C677T (N= 397) 2 
CC 1 175 98 1.00 4- 32 89 7.23 1.5-33.8 001 
CT/n 6 166 97 2.00 0.5-8.0 033 9 51 85 10.56 2.7-41.4 <0.01 
pror 0.39 
interaction 
MTHFR A1298C (N= 397) 2 
AA 4 - 192 97 1.00 6 42 88 4.88 1.5-16.0 <0.01 
ACJCC 3 149 98 0.63 0. 2~2.5 0.51 7 41 85 5.52 1.7-17.6 <0.01 
PfOf 0.59 
interaction 
'Adju sting tor clinical covariates stage at diagnosis, chemotherapy use. ER-status d id not affect point estimates by more than 10%; 
' Only baseline DNA included in the anatyses. 
In these analyses, the referent group was women homozygous for the 
major allele and did not receive chemotherapy as part of their treatment following 
breast cancer diagnosis. For BHMT A742G, breast cancer-specific mortality was 
higher among those with AA genotype who received chemotherapy (HR: 3.26; 
95% CI: 0.8-13.8; p- value: 0.11) compared to those with the same genotype who 
did not receive chemotherapy (table 17). Among women who did not receive 
chemotherapy, the AG/GG genotype had a non-significant inverse association 
with breast cancer-specific mortality (HR: 0.81; 95%CI: 0.2-3.3; p- value: 0.77) 
compared to carrying the AA genotypes (figure 18). Women with the same 
genotype who received chemotherapy had significantly increased breast cancer-
specific mortality rates (HR: 8.59; 95%CI: 2.4-30.7; p- value: <0.01) compared to 
not carrying the variant allele who did not receive chemotherapy suggesting a 
possible synergistic effect of the polymorphism and chemotherapy on breast 
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Figure 17: Kaplan-Meier survival curves among carriers of the BHMT 
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Figure 18: Kaplan-Meier survival curves among carriers of the BHMT 
A742G, AG/GG genotype stratified by chemotherapy, HEAL study, New 
Mexico (N= 446) 
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For SHMTG1420A polymorphism, women with GG genotype, who received 
chemotherapy were at increased risk of breast cancer-specific mortality (HR: 
3.73; 95% CI: 1.0-13.9; p-value: 0.05) compared to women without 
chemotherapy (figure 19). Women with the variant alleles of the polymorph isms 
(GA/AA) who did not receive chemotherapy had inverse association with breast 
cancer-specific mortality (HR: 0.56; 95% CI: 0.1-2.3; p- value: 0.44) (figure 20) 
while those with the same genotype who received chemotherapy were at 
increased breast cancer-specific mortality rates (HR: 6.49; 95% CI: 1.9-21.9; p-
value: <0.01) compared to women with the homozygous dominant genotype 
(GG) without chemotherapy suggesting a borderline synergistic effect of SHMT 
G1420A polymorphism and chemotherapy on breast cancer-specific mortality (p 
for interaction: 0.21). 
No significant interactions with chemotherapy were observed with the 
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Figure 19: Kaplan-Meier survival curves among carriers of the SHMT 
G1420A, GG genotype stratified by chemotherapy, HEAL study, New 
Mexico (N= 446) 
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Figure 20: Kaplan-Meier survival curves among carriers of the SHMT 
G1420A, GA/AA genotype stratified by chemotherapy, HEAL study, New 




Interaction with ER-status: 
To investigate if ER-status modifies the effect of the genes in the folate 
metabolizing pathway on breast cancer-specific mortality, the associations 
between the polymorph isms and breast cancer-specific mortality stratified by ER 




Table 17: Age. adjusted breast cancer.specific mortality stratified by ER status and genotype in the New Mexico 
samples of the Health, Eating', Activity, and Lifestyle Study (n= 446). 
, , 
Gellotype Deaths Censored : H'alan.l Rl1tio1 i P- Deaths ; Censoled Haz.ard Ratio1 p-
N N % 95% CI value N N % 95% CI value 
. ER- Positive . . . r ER· Negative 
. -_ ..................... , .. ·~ .. ··········-· .... ····· .. · .. BflMr A741:G'tN'';;'''313) ............................. _-_ ................................ . 
r ..... ·.p.::J;.·, .. · ··"1-2'O·'·-9Tf"··'·'···1]JO~ ··· .... r· .. ·· .. ·'-;-.. ···3 ·····:··· '2,ij······SO·.,.,··4:3J · O:·9:2' ~·:5··-···0·:01·· .. 
AG/GG ' 127 95 2. 18 0.6-8.4 : 0.26 ' 4 ... 23 85 , 6.21 1.3-28.7 0.01 ' 
' ;::> '61 ........... 069- .• ~ , .n. .. • .• 
i'1ieraCiion 
A1TRAll56G (Nd 313J . 
.. AA" ' T-" 'S ".': i5X" g4 '~' ., r oo":" ... ":. 2 ···' .. ··29· '''g,:l ; .. 1' 09 '02:5 f <', 091 
AG/GG j 2 93 98 . 0.37 0117 : 019 : 4 . 20 83 : 2,92 0997 008 
• ,····;::1'100/· , ... :- ........ N.· ..... ..... --.• ~ •••• '........... , ..... ". • ........ 0.11 ... , .................... "" 
. interaction 
\I. - , .. ," ,. .." . MrRR GGGA (t~- 313) 
. · .. ,,·GG······, "5 ·6'2···· .. ·91 ... · ""'1.00 "", ",- ...... '.'., ... 2" ... ;". 1'3 'go' ',(", --1:06'''02-5:'3' ;' 0:95 
86 1.51 0.5-5.1 i 0.50 ! GAJAA 4 185 98 0 .. 23 O . 1~0. 8 0.02 5 : 31 
;.. ? fOr .. ,." 0'. 11 
t?:erac 00. 
"""""; 
. SHMT G'14,70A '(N ;'" 313)' 
4'" 1'25 97 r '1. 00"; .. 4- 25 '" ' 86 4.41 1.1-17'9 '003 GG 
G 122 95 i 151 0.4·5.4 · 0,52 : 3 
." • ., •• -,., - ~ -0' -,,, •• , {LS7' 24 89 3,68 O,8-1G,G ' 0.09 GlAJAA ' , ,~ .. prOf "'; 
interaction 
·A.djUstlng forcllnlcal covarlates stage at 0lagnosl8 , chemotherapy use, ER-status ala 110£ affect pOint estimates by more man 10'%: 
'only oaseline ONA inCluaea In the analyses. 
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\.D 
Table 17continued: Age- adjusted breast cancer-specific mortality stratified by ER status and genotype in the 














Deaths Censored Hazard Ratio 1 P - Deaths Censored Hazard Ratio ' p . 
N N % 95% CI value N N % 95% CI value 
ER- Positive ER. Negative 
FOLR1 G606A (N;;; 313) 
3 119 98 1. 00 . 3 25 89 4.32 0.9-21.5 0.07 
7 128 95 2.19 0.6-8.5 0.26 4 24 95 6.07 1.3-27.3 0.01 
0.67 
MTHFR csm {N= 391)2 
2 
6 
131 97 1.00 2 17 89 3.60 0.7·19.8 0 14 
3 
5 
122 95 1.60 0.5S7 046 5 26 84 5.59 1_5·21 .1 0.01 
0.72 
MTHFR A 1298C (N= 397) 2 
139 97 1.00 .4 23 85 4.54 1.2-17.1 0.03 
114 96 1.20 0.3-4.1 0.77 3 20 87 3.59 0.8-15.2 0.08 
0.54 
l Adjusting forclinical covariates stage at diagnosis, chemotherapy use, ER-status did not affect point estimates by more than 10%: 
' Only baseline DNA included in the analyses. 
In these survival analysis models, in the referent group was women with the 
homozygous dominant genotype with ER-positive tumor. For MTR A2756G, for 
women with AA genotype, there was no association between women with ER-
negative tumors and breast cancer-specific mortality compared to women with 
ER-positive tumor (figure 21). Figure 21 shows violation of the proportional 
hazard assumption. Among women who carried at least one variant allele of the 
polymorphism (AG/GG), those with ER-positive tumor had an inverse association 
with breast cancer-specific mortality (HR: 0.37; 95% CI: 0.1-1.7; p-value: 0.19) 
(figure 22), while women with ER-negative tumor had significantly increased risk 
for breast cancer-specific mortality (HR: 2.92; 95% CI: 0.9-9.7; p-value: 0.08) 
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Figure 21: Kaplan-Meier survival curves among carriers of the MTRR 
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Figure 22: Kaplan-Meier survival curves among carriers of the MTRR G66A, 
GA/AA genotype stratified by ER-status, HEAL study, New Mexico (N= 446) 
For MTRR G66A polymorphism, there was no association between women with 
ER-negative tumor and GG genotype and breast cancer-specific mortality 
compared to women with the same genotype and ER-positive tumor (figure 23) . 
The Kaplan-Meier curve in figure 23 shows the violation of the proportional 




variant allele of the polymorphism (GA/AA) , there was significant inverse 
association among women with ER-positive tumor and breast cancer-specific 
mortality (HR: 0.23; 95% CI: 0.06-0.79; p-value: 0.02) compared to women with 
GG genotype and ER-positive tumor (figure 24). There was non-significant 
association between women with ER-negative tumor and GA/AA genotype and 
breast cancer-specific mortality (HR: 1.51; 95% CI: 0.5-5.1; p-value: 0.50) 
compared to women with GG genotype and ER-positive tumor suggesting 
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Figure 23: Kaplan-Meier survival curves among carriers of the MTR 
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Figure 24: Kaplan-Meier survival curves among carriers of the MTR 
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This chapter summarizes the findings of the dissertation project and 
provides potential interpretations that establish integration between biochemical 
mechanisms of the folate metabolizing pathway reported in the literature and the 
statistical findings of the current study. Strengths and limitations of this 
dissertation are evaluated also. 
In this population-based breast cancer cohort with 446 participants from 
New Mexico, 5% of the study participants died due to breast cancer related 
complications within the 11.46 years of follow-up. Since 1990 there has been a 
steady decline in the breast cancer-specific mortality rates mostly due to early 
detection, advancement in treatment options and decreased incidence 1. 
Although the literature on the genes in the folate metabolizing pathway and their 
influence on breast cancer survival are limited, studies have investigated the 
associations between MTHFR polymorph isms and breast cancer risk 11-17. The 
genes in the folate metabolizing pathway are responsible for enzymes that 
maintain DNA methylation, synthesis and repair2 7 8. Since abnormal DNA 
synthesis and repair may lead to carcinogenesis and irregularity in DNA 
methylation may modify response to chemotherapl6, genes in the folate 
metabolizing pathway may influence breast cancer survival. 
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AIM1: MAIN EFFECTS 
In this exploratory study, MTRR G66A had a statistically significant 
inverse association with breast cancer-specific mortality and all-causes mortality. 
Similar inverse associations were also observed in the Long Island Breast 
Cancer study (Breast cancer-specific mortality: HR: 0.77; 95% CI: 0.49-1.23; all-
causes mortality: HR: 0.75; 95% CI: 0.52-1.08)19. Non-significant associations 
were also observed between four SNPs, MTR G66A, BHMT A742G, SHMT1 
G1420A, and FOLR1 G606A and breast cancer-specific mortality. In the New 
Mexico sample, unlike the larger HEAL sample, there was positive association 
between MTHFR C677T and breast cancer-specific mortality. 
AIM 2: GENE - GENE INTERACTION 
Significant and borderline gene-gene interactions were observed 
between FOLR1 G606A and BHMT A742G polymorph isms and between MTRR 
G66A and MTHFR C677T polymorphisms respectively. 
Potential interpretations for gene-gene interactions: 
Gene-gene interaction between FOLR1 G606A and BHMT A742G (p for 
interaction: 0.03) in predicting breast cancer-specific mortality was observed in 
this sample. One of the reasons for interaction may be related to their respective 
functions in the folate metabolizing pathway. The role of FOLR1 is to bind with 
folic acid and its derivatives and facilitate transportation of 5-methyITHF. The 
role of BHMT enzyme is the re-methylation of homocysteine to methionine47 , a 
process which uses 5-methylTHF transported by FOLR1. Variations in FOLR1 
may influence the levels of 5-methyITHF, while variation in BHMT polymorph isms 
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may compromise the conversion of homocysteine to methionine. The plausibility 
of this argument is supported by the synergistic effect of the two polymorph isms 
of these genes in predicting breast cancer survival. Hence, each of these 
polymorph isms may modify the effect of the other in predicting breast cancer-
specific mortality. 
In this exploratory study, a statistically significant interaction between 
MTRR G66A and MTHFR C677T (p for interaction: 0.08) in predicting breast 
cancer-specific mortality was observed also. Biochemical studies suggest that 
MTHFR acts as a catalyst in the conversion of 5, 10-methylHF to 5-methylTHF, 
which serves as a donor for the re-methylation of homocysteine to methionine 9. 
Methionine synthase reductase activates methionine synthase by acting as a 
carbon donor for homocysteine re-methylation and substitutes isoleucine with 
methionine43 . Variations in MTHFR and MTRR polymorph isms may, therefore, 
influence homocysteine levels, although in different directions. Since studies are 
inconsistent about the direction of the association between MTRR polymorphism 
and homocysteine levels 43 and it is also unknown if homocysteine levels are 
associated with breast cancer-specific mortality in this population, the 
antagonistic effect observed in this exploratory study should be interpreted with 
caution. In spite of low to moderate power of this study (tables 5 and 6, chapter 
III) women carrying the variant alleles for both polymorphism had statistically 
significant reduced breast cancer-specific mortality rates compared to women 
carrying the homozygous dominant genotypes for both polymorphism while 
significantly increased breast cancer-specific mortality was observed among 
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women carrying variant allele for MTHFR C677T and homozygous GG genotype 
for MTRR G66A. 
AIM 3: GENE - ENVIRONMENT INTERACTION 
Although it did not reach statistical significance, chemotherapy modified 
the effects of BHMT A742G and SHMT1 G1420A. In this sample, there were 
also borderline significant interactions between ER-status and MTRR G66A 
polymorphism and MTR A2756G polymorphism. 
Potential interpretations for gene-environment interactions: 
In this sample, women carrying the AG/GG genotype of BHMT A742G 
polymorphism who received chemotherapy may have elevated rates of breast 
cancer related deaths. The apparent synergistic effect of chemotherapy with 
BHMT A742G polymorphism may be supported by the following arguments. Two 
common chemotherapeutic agents 5 FU and MTX affect DNA synthesis and 
down-regulate cell replication. 5'-formyITHF, the precursor of 5, 10-
methyleneTHF potentiates the cytotoxic effects of 5-FU by stabilizing the 
inhibition of 5, 1 O-methyleneTHF-TS- 5FdUMp6o. MTX inhibits dihydrofolate 
reductase, decreases intracellular 5,10 -methyleneTHF levels for the synthesis 
of thymidylate and inhibits the synthesis of purine61 . Although not directly 
involved in folate metabolism, BHMT helps in the conversion of homocysteine to 
methionine by donating carbon when the re-methylation process is compromised 
due to genetic and/or dietary factors47 . It is also suggested to be associated with 
homocysteine levels47 . Although future research should confirm the findings of 
this exploratory study, it is plausible that since chemotherapy may influence DNA 
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synthesis and repair and the BHMT A742G polymorphism may affect the 
methylation process, the two simultaneous processes may result in the elevation 
of the breast cancer-specific mortality. 
In this study, there was also borderline interaction between chemotherapy 
and SHMT G1420A polymorphism. It has been suggested that carriers of the 
minor allele of SHMT G1420A polymorphism may decrease the production of the 
5-10-methyITHF for pyrimidine synthesis which may reduce the levels of DNA 
methylation through negative feedback resulting in decreased 5-methylTHF 
production and accumulation of THF53. The common chemotherapeutic agents 
5FU and MTX interferes with the levels of 5-1 O-methylTHF and increases their 
cytotoxic effects resulting in abnormal DNA synthesis6o. Owing to the synergistic 
effect of the variant allele and the effect of chemotherapy women who received 
chemotherapy and carried at least one variant allele of SHMT G1420A 
polymorphism may have increased breast cancer-specific mortality rates 
compared to carriers of the homozygous dominant genotype GG who did not 
receive chemotherapy. 
Studies have suggested that DNA methylation may be associated with 
inhibition of ER expression66-69. Binding of estrogen to the ER is thought to 
stimulate mammary cell proliferation, which may lead to decrease in cell division, 
DNA replication and mutation 114. Although studies have reported the presence of 
association between MTR A2756G and plasma homocysteine in humans, the 
results are inconsistent for the levels of homocysteine across genotypes of 
A2756G34-36 . Like the MTR polymorphism, although studies are consistent about 
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the association between homocysteine levels and MTRR G66A there is 
inconsistency in the literature regarding the direction of the association44-46 . 
Thus, variations in either of these polymorph isms may compromise DNA 
methylation which could be associated with ER-induced carcinogenesis. Future 
studies in this area may explain the synergistic of these polymorph isms and ER 
status. 
STRENGTHS 
One of the strengths of this study is that although the sample for this 
population based case cohort is relatively small it has a maximum follow-up time 
of 11.5 years. Secondly, no other study has so far investigated the interactions 
among the genes in the folate metabolizing pathway and breast cancer-specific 
mortality. Interactions of the genes in the folate metabolizing pathway with 
chemotherapy and ER-status were also investigated. Since the enzymes 
associated with these genes in the folate metabolizing pathway influence each 
other and are known in the biochemical literature to be influenced by prognostic 
markers of breast cancer, it is important to investigate the effects of these 
interactions in predicting breast cancer-specific mortality. Hence, the study is an 
important contribution to the literature on folate metabolizing pathway and breast 
cancer-specific mortality. 
LIMITATIONS 
One of the potential limitations of this dissertation project is its small 
sample size. However, the study participants were followed for a maximum of 
11.5 years which helped enhance the power of the study to a great extent. 
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Secondly, in this study only the samples from New Mexico site of the HEAL study 
were used. The sample consisted of 22% Hispanic and 78% non-Hispanic white 
ethnicity. There was, however, limited power to investigate ethnic-specific 
associations. Third, the study also had limited power to investigate the effects of 
folate and B- complex vitamins on the association of these genes in the folate 
metabolizing pathway and breast cancer mortality. Although interactions with 
chemotherapy and genes in the folate metabolizing pathway in predicting breast 
cancer-specific mortality rates were investigated, effect modifications with 
individual chemotherapeutic regimens and breast cancer-specific mortality could 
not be studied due to lack of power. Potential three way interactions may exist 
between genes in the folate metabolizing pathway in predicting breast cancer-
specific mortality rates, but was unable to investigate due to limited sample size 
in this study. 
Fourth, all analyses in this dissertation were based on dominant models. 
It would be of interest to know the strengths of the associations between genes in 
the folate metabolizing pathway and breast cancer-specific mortality and all-
causes mortality when other models are used but owing to limited power in this 
cohort, results of other model types would be unstable. 
Fifth, the current study did not investigate three other genes that influence 
folate metabolism: dihydrofolate reductase (OHFR) and thymidylate synthetase 
(TYMS or TS) and replication factor C1 (RFC1), which were studied in the Long 
Island Breast Cancer Studi 9 and have been investigated by researchers who 
have studied the pathway in relation to etiology of other cancers. TYMS and 
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OHFR serve important roles in folate metabolizing pathway. TYMS catalyzes the 
conversion of dUMP is to dTMP, which is important for DNA synthesis and 
repair115, while 5,10-methylene-THF, a substrate of TYMS, is obtained from 
thymidine synthesis, purine synthesis, and DNA methylation21 . Commonly used 
chemotherapeutic agents., 5-FU and MTX, affects TYMS and OHFR and 
thereby block DNA synthesis and cell replication 19. However, unlike the SNPs 
corresponding to MTHFR, BHMT, MTR, MTRR and SHMT genes, where there 
was only one nucleotide change among the two variants of the polymorphs, 
TYMS, with repeats at 5'-untranslated region (5'-UTR) and insertion-deletion at 
3'- UTR and OHFR, which is a 19 bp deletion, requires more advanced 
laboratory capabilities than were available for this research and therefore were 
not included. Like FOLR1, RFC1 is responsible for transportation of 5-
methylTHF from plasma to cytosol116. Although a commonly investigated SNP, 
A80G (rs1051266) polymorph of RFC1, was not investigated in this dissertation 
because its population allele frequency (Minor allele frequency: 0.45), was 
beyond the range that was set a priori for a SNP to be eligible for investigation in 
this study (refer to chapter 3 for eligibility criteria for SNP selection). 
Sixth, in the preliminary study the association between MTHFR 
polymorphisms and breast cancer survival (see Chapter IV for details) was 
investigated using data from all three HEAL Study sites(N= 772). Unlike the 
dissertation project where both baseline and follow-up data were used, only 
baseline DNA was used while genotyping the MTHFR polymorph isms. In the 
preliminary study sample, 41 out of the 107 women who died during the follow-up 
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were from the New Mexico site. For the current project, there was insufficient 
archival DNA left for genotyping 22 out of the 41 women leading to a systematic 
selection bias in the sample used in this dissertation. The effect of this bias is 
reflected in the point estimates of the MTHFR polymorph isms in the two studies 
(compare table 9, chapter IV and table 14, chapter V). In the larger sample, 
carriers of the variant alleles of MTHFR C677T (CTITT: HR: 0.76; 95% Cl: 0.5-
1.10) and MTHFR A 1298C (AC/CC: HR: 0.71; 95% Cl: 0.48-1.05) 
polymorph isms had an inverse association with breast cancer-specific mortality. 
The direction of the association between MTHFR C677T and breast cancer-
specific mortality reverses when the analysis is restricted to the New Mexico 
sample (CTITT: HR: 2.17; 95% Cl: 0.8-5.9). 
Lastly, the current research also did not take into consideration 
competing risks which may have influenced mortality. Previous work has 
suggested that the genes in folate metabolizing pathway influence the etiology of 
colon cance,-21 227693. It is, therefore, intriguing to test what percentage of the 
deaths due to cancer other than breast cancer in this sample could be 
attributable to colon cancer and if they serve as confounding factors in the 
association between the genes in the folate metabolizing pathway and breast 
cancer survival. Studies have shown that higher concentration of homocysteine, 
an amino acid involved in SAM synthesis, elevates the risks of CVD 9495 and 
MTR, BHMT, MTRR, and MTHFR catalyzes the conversion of homocysteine to 
methionine by remethylation (chapter II, figure 1). Homocysteine is excreted by 
the kidney in moderate amounts96 but polymorph isms of genes involved in 
102 
homocysteine metabolisms could increase the plasma concentration of 
homocysteine 9798 which is suggestive of increasing the risk for CV0991OO . Since 
the genes in the folate metabolizing pathway may be involved in altering CVO 
mortality, it may be considered an important competing risk against the 
association between genes in folate metabolizing pathway and breast cancer 
mortality. In spite, of its importance in the literature on the folate metabolizing 
pathway, it could not be investigated in the current dissertation project owing to 
limited power. 
CONCLUSION 
To summarize, genes in the folate metabolizing pathway may play an 
important role in breast cancer-specific mortality. Gene-gene interactions and 
interactions between prognostic markers like chemotherapy and ER-status and 
the genes in the folate metabolizing pathway may influence breast cancer-
specific mortality. Because folate metabolism is a complex interconnected 
mechanism, future research should further investigate the findings of this study 
and help integrate the biochemical mechanisms of the folate metabolizing 
pathway with statistical findings of Genetic Epidemiological studies. It will also 
be valuable to the literature on the folate metabolizing pathway, if future studies 
investigate the effects of these genes on disease-free survival following breast 
cancer diagnosis and the role of completing risks on all-causes mortality. Larger 
cohort and randomized control trails should investigate the finding of the current 
study in relation to breast cancer survival. 
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APPENDIX I 
LIST OF ABBREVIATIONS 
BHMT: betaine-homocysteine-methyltransferase 
BMI: Body Mass Index 
CVD: Cardiovascular Disease 
DHF: dihydrofolate 
DHFR: dihydrofolate reductase 
DNA: Deoxyribonucleic acid 
dTMP: deoxythymidine monophosphate 
dUMP: deoxyuridine monophosphate 
ER: estrogen receptor 
FOLR1: Folate receptor 1 
HR: Hazard Ratio 
HEAL: Health, Eating, Activity and Lifestyle study 
MTHFR: methylenetetrahydrofolate reductase 
MTRR: 5-methyltetrahydrofolate-homocysteine methyltransferase reductase 
MTR: 5-methyltetrahyd rofolate-homocystei ne 
MTX: Methotrexate 
PR: progesterone receptor 
RFC: reduced folate carrier 




SHMT1: serine hydroxymethyltransferase 1 
SNP: single nucleotide polymorph isms 
THF: tetrahydropfolate 
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TAQMAN SNP GENOTYPING 
RT-PCR uses TaqMan SNP genotyping assay which includes two PCR 
primers specific to the locus under investigation that flanks the SNP, and two 
oligonucleotide TaqMan probes specific to the allele of interest. Each probe has 
fluorescent dye at the 5' end and a non-fluorescent quencher with a minor grove 
binder (MGB) at the 3' end 111 . The two fluorescence dyes used here are FAM 
and VIC. Conventionally the major allele of a SNP is identified by the FAM while 
the minor allele is identified by the VIC dye. TaqMan genotyping uses a universal 
master mix to detect the variants of the six SNPs. In a nut-shell, during each 
PCR cycle, the probe which is hydrolyzed to the allele of interest, emits a 
fluorescent signal when it cleaves to the 5' exonuclease action of the AmpliTaq 
Gold DNA Polymerase. The primers amplify the locus of interest in the DNA 
template and the dye specific to the alleles reports the presence or absence of 
the allele in the DNA sample112113. Taq polymerase, which is isolated from 
thermophillic bacteria, is capable of withstanding very high temperatures, hence 
used for the purpose. The presence of two probes, each specific to an allele of 
the SNP under investigation and labeled with two dyes, enables two alleles to be 
detected in a single tUbe 113. The following is an animated version of the 
technique shown in three chronological steps. 
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Figure 26: Animated representation of the 5' nuclease TaqMan assay 
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Step 2: Annealing the components of TaqMan assay 
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Below is the protocol developed for genotyping the six SNPs: 
Steps for Genotyping: 
Instructions to make working and reaction plates for genotyping using RT-PCR 
Prepare for bench work: 
1. wipe the work bench with O.01X bleach solution 
2. layout a long sterile sheet 
3. Wear gloves 
Working plate: 
1. Dilute 1X TE buffer to O.1X by adding de-ionized or double distilled water. 
2. Label each working plate. Be as complete as possible <WP _Experiment 
name_SNP ID_plate #> 
3. Four designated wells are considered as controls and are filled with de-
ionized water. Make sure they are spread out randomly across the plate. 
(Consult the template for their exact location). Keep their positions 
constant for all plates for convenience. 
4. Get the DNA box out of the freezer 
5. Thaw each vial by rubbing it with hand in circular motion 
6. Allocate required amount of DNA into the labeled working plate well and 
dispose the pipette tip (consult excel sheet for DNA volume and 
concentration) 
7. Using another pipette tip, allocate required amount of TE into each well. 
To determine the amount of DNA and O.1X TE required to make working 
plates is derived from the equation: 
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=> V1 = [C2V2]/ C1 
Here, C1= Initial DNA concentration 
working plate 
V1= Total final volume of DNA after addition of 0.1X TE 
C2= Final DNA concentration 
V2= Final volume of DNA and 0.1X TE mixture in each well of the 
For example, for DNA with initial concentration of 47ng/jJL (C1), we 
allocate 75jJL of 0.1X TE to 2jJL of DNA (V1), 
Volume of DNA needed = [2 X 75]/47 
-3 
Volume of 0.1 X TE needed= 75 - 3 = 72 
In other words, we allocated 3jJL of DNA (of 47ng/jJL concentration) in 
each plate and added 72jJL of 0.1 X TE to make our working stock. Here, 
enough DNA-TE mixture is made as working stock to allow room for 
evaporation. 
8. Mix the DNA and the TE by using the pipette (counting 1-15 help) 
9. Repeat step 2-6, 92 times to fill 92 wells for the working plate 
10. Seal the plate with adhesive covers (less expensive non-optical works 
fine) making sure the edges are smoothed tightly. 
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11. Centrifuge for 1 minute at 1200 rpm if you are ready to prepare reaction 
plates. Otherwise, cover with aluminum foil and store in refrigerator for 6-8 
months. If stored for long check the amounts in each well for evaporation. 
Reaction plate: 
1. To prepare the reaction mixture for a particular SNP we need to start with 
mixing required amounts of assay, de-ionized water and master-mix in a 
reservoir used for multi-channel pipettor. Consult corresponding charts to 
ensure the exact amount required for one plate times the total number of 
plates that will be run in the RT-PCR on a particular lab day (table 18). As 
the name suggest, in a 96 well plate, there are 96 wells. To make reaction 
mixture for one well, we need 
2X master mix: 10IJL 
40X assay: 0.5 IJL 
De-ionized water: 4.51JL 
Total: 10IJL 
However, additional amount of 10-15% made for each plate to account for 
evaporation. Therefore, after accounting for the excess, for one plate, we 
made a reaction mixture of the following: 
2X master mix: 
40X assay: 
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De-ionized water: 540IJL 
Total: 1800IJL 
Below is a quick look at the amounts corresponding to each of the three 
ingredients required to prepare reaction mixtures 
Table 18: Amounts of ingredients required to make reaction mixtures: 
# of # of additional 2X Master 40X Water Total 
plates wells Amts* Mix assa~ 
1 10 0.5 4.5 15 
1 96 120 1200 60 540 1800 
2 192 220 2200 110 990 3300 
3 288 330 3300 165 1485 4950 
4 384 450 4500 225 2025 6750 
5 480 540 5400 270 2430 8100 
6 576 660 6600 330 2970 9900 
The "total " column can be double checked by multiplying column "additional 
amts" by 15; for example, 330 X 15 = 4950. Stocks can be stored in the 
refrigerator for no more than 2-3 days. 
2. Label each reaction plate. Be as complete as possible <RP _Experiment 
3. Using an 8 tip pipettor, allocate required amount of standardized DNA-TE 
into all 96 wells (Consult the template for each experiment for the exact 
location of each 10). Dispose the pipette tips after every row. 
4. Using an 8 tip pipettor, pipette the master-mix cocktail into the wells , one 
row at a time. Dispose the tips after every row. 
5. Once all the 96 wells are filled , seal the plate with optical adhesive cover 
6. Centrifuge the plate for 1 min at 1200 rpm. 
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7. Open the relevant template in the computer/RT-PCR corresponding to the 
experiment. 
8. In the "Advance Set-up" tab type in the experiment name and number, and 
select the following tabs: 
• Step-one Plus instrument (96 well plates) 
• Genotype 
• TaqMan reagent 
• Standard (speed) 
The rest of the conditions are pre-set. 
9. In the "Plate Set-up" tab, double check the" View plate layout" and "View 
well table" to make sure the right templates are open for the experiment 
1 O. Stick the plate into the RT-PCR and let the reaction begin. The reaction 
last for about 1 hr 30 mins to complete. 
11. Once the reaction is over check if the controls are correctly detected. 
12. Save the output in the computer and the USB drive. 
Thermal cycler: 
13. While one plate is running in the RT-PCR machine, a second one can be 
inserted in the thermal cycler. Select "SNP assay PCR" and click "run". 
The reaction last for about 1 hr 30 minutes. 
14. Once it is over, if the RT-PCR is running a plate or you are running out of 
time for the day at the lab, it is okay for the plate to be stored in the 
refrigerator for a day. Just remember to (a) cover it with aluminum foil prior 
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to storage and (b) centrifuge the plate for 1 min at 1200 rpm prior to 
running it on the RT-PCR machine. 
15. Make sure you have opened the right template for the reaction. 
16.ln the "Run Methods" tab, open the Graphical view tab, select and delete 
the following sections: 
• Pre-PCR Reading (Holding stage) 
• Holding Stage 
• Cycling Stage 
Only the final step, called the "Post-PCR Read (Holding Stage)" where the 
end point of the reaction is processed in the RT _PCR machine. 
17. Make sure options "Pre-PCR Reading" and "Amplification" are checked. 
18. Insert the plate in the RT-PCR machine and click "run". 
19. Reaction will last for approximately 2 minutes. 
20. Once the reaction is over check if the controls are correctly detected. 
21. Save the output in the computer and the USB drive. 
If there is not enough time on the day reaction plates are prepared, the reaction 
plates can be stored in the refrigerator (for about 2-3 days) after step 6 is 
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